<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ANGELIQ- estradiol and drospirenone tablet, film coated </strong><br>Bayer HealthCare Pharmaceuticals Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ANGELIQ safely and effectively.  See full prescribing information for ANGELIQ.<br>ANGELIQ (drospirenone and estradiol) tablets, for oral use<br>Initial U.S. Approval: 2005</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER and <br>PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy</span></span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>, <a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a> )</span></dd>
<dt>•</dt>
<dd><span class="Bold">The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (<a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e">5.3</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>, <a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<dl>
<dt> </dt>
<dd>Warnings and Precautions, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> (5.2)	 6/2015</dd>
</dl>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER and <br>PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy</span></span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>, <a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a> )</span></dd>
<dt>•</dt>
<dd><span class="Bold">The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer (<a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>)</span></dd>
</dl>
<p class="Highlighta"><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span> </p>
<dl>
<dt>•</dt>
<dd><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens (<a href="#i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e">5.3</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>, <a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age and older (<a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Angeliq 0.25 mg drospirenone (DRSP)/0.5 mg estradiol (E2) is an estrogen/progestin indicated in women with an intact uterus for the treatment of: </p>
<dl>
<dt>•</dt>
<dd>Vasomotor symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. (<a href="#i4i_section_id_c442810c-392f-489a-beb3-4d9ced29f504">1.1</a>)</dd>
</dl>
<p class="Highlighta">Angeliq 0.5 mg DRSP/1 mg E2 is an estrogen/progestin indicated in women with an intact uterus for the treatment of: </p>
<dl>
<dt>•</dt>
<dd>Vasomotor symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. (<a href="#i4i_section_id_c442810c-392f-489a-beb3-4d9ced29f504">1.1</a>)</dd>
<dt>•</dt>
<dd>Vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>. (<a href="#i4i_section_id_b13d5922-6a1e-4a4a-9d55-ee4b62a73b7b">1.2</a><span class="Underline">)</span>
</dd>
</dl>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Angeliq 0.25 mg DRSP/0.5 mg E2: one tablet taken by mouth once daily (<a href="#i4i_section_id_ecbe5f61-6f73-44ea-a1eb-62e083d437d4">2.1</a>) </p>
<p class="Highlighta">Angeliq 0.5 mg DRSP/1 mg E2: one tablet taken by mouth once daily (<a href="#i4i_section_id_ecbe5f61-6f73-44ea-a1eb-62e083d437d4">2.1</a>, <a href="#i4i_section_id_e2b3ce6b-69b9-4537-9b09-df4d5a2b85d0">2.2</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Angeliq 0.25 mg DRSP/0.5 mg E2 tablet: one tablet contains 0.25 mg drospirenone and 0.5 mg estradiol, (<a href="#i4i_dosage_form_strength_id_5d949692-9341-4172-870c-f0862a58dd37">3</a>)</dd>
<dt>•</dt>
<dd>Angeliq 0.5 mg DRSP/1 mg E2 tablet: one tablet contains 0.5 mg drospirenone and 1 mg estradiol (<a href="#i4i_dosage_form_strength_id_5d949692-9341-4172-870c-f0862a58dd37">3</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>)</dd>
<dt>•</dt>
<dd>Known, suspected, or history of cancer of the breast (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>, <a href="#i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e">5.3</a>)</dd>
<dt>•</dt>
<dd>Known or suspected estrogen-dependent neoplasia (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>, <a href="#i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e">5.3</a>)</dd>
<dt>•</dt>
<dd>Active DVT , PE, or a history of these conditions (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>, <a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a> )</dd>
<dt>•</dt>
<dd>Active arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and MI), or history of these conditions (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>, <a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>, <a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a>)</dd>
<dt>•</dt>
<dd>Known liver impairment or disease (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>, <a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal insufficiency</span> (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>, <a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a>)</dd>
<dt>•</dt>
<dd>Known or suspected pregnancy (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>, <a href="#i4i_pregnancy_id_025aeb73-b3c3-4d73-9eb1-df9c2a74e4d2">8.1</a>)</dd>
<dt>•</dt>
<dd>Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>)</dd>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, or  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Angeliq (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Do not use with conditions that predispose to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (<a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a>)</dd>
<dt>•</dt>
<dd>Estrogens increase the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> (<a href="#i4i_section_id_02a9753d-3e85-4d47-954f-30ed78cb9d9f">5.5</a>)</dd>
<dt>•</dt>
<dd>Discontinue estrogen if severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, severe <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> or <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> occurs (<a href="#i4i_section_id_7dab8756-4e5a-4e15-ab39-e13d83cdbf7b">5.6</a>, <a href="#i4i_section_id_7b576ab6-a487-4b1e-a241-8faef65e475c">5.7</a>, <a href="#i4i_section_id_4c149f4e-413e-4afb-86f9-ead7215a3ad1">5.9</a>, <a href="#i4i_section_id_ac3343a4-0573-49b0-af06-e2b47e51979d">5.10</a>)</dd>
<dt>•</dt>
<dd>Monitor thyroid function in women on thyroid replacement therapy (<a href="#i4i_section_id_f43a3bbe-5b99-4f41-abfc-472f05135718">5.11</a>, <a href="#i4i_section_id_e96d0a31-ae9e-43c1-87c9-304133e9547d">5.19</a>)</dd>
</dl></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> The most common adverse reactions that occurred in at least 1 percent of users in clinical trials with Angeliq are gastrointestinal and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, female genital tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> and <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. (<a href="#i4i_section_id_2a37b7ef-24f2-4433-93ea-e47f7fa881fc">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Inducers and inhibitors of CYP3A4 may affect estrogen drug metabolism and decrease or increase the estrogen plasma concentration (<a href="#i4i_section_id_89709cc7-b783-4ecb-b0d8-34ade23dee53">7.1</a>)</dd>
<dt>•</dt>
<dd>Serum potassium concentration may increase in women taking drospirenone with other drugs that have the potential to increase potassium (<a href="#i4i_section_id_89709cc7-b783-4ecb-b0d8-34ade23dee53">7.1</a>)</dd>
</dl></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Nursing Mothers: Estrogen administration to nursing women has been shown to decrease the quantity and quality of breast milk. (<a href="#i4i_nursing_mothers_id_67f1c69f-114e-44e1-a777-ae01523f3ac1">8.3</a>)</dd>
<dt>•</dt>
<dd>Geriatrics<span class="Bold">:</span> An increased risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women over 65 years of age was reported in the Women's Health Initiative Memory ancillary studies of the Women’s Health Initiative. (<a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>, <a href="#i4i_geriatric_use_id_953cda66-db43-4afe-998c-fc07588263ab">8.5</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 7/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> </a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Malignant Neoplasms </a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span> </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> </a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Visual Abnormalities </a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Elevated Blood Pressure </a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> </a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span> </a></h2>
<h2><a href="#section-5.11" class="toc">5.11 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> </a></h2>
<h2><a href="#section-5.12" class="toc">5.12 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> </a></h2>
<h2><a href="#section-5.13" class="toc">5.13 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> </a></h2>
<h2><a href="#section-5.14" class="toc">5.14 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> </a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> </a></h2>
<h2><a href="#section-5.16" class="toc">5.16 <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span></a></h2>
<h2><a href="#section-5.17" class="toc">5.17 Exacerbation of Other Conditions </a></h2>
<h2><a href="#section-5.18" class="toc">5.18 Laboratory Tests </a></h2>
<h2><a href="#section-5.19" class="toc">5.19 Interference with Laboratory Tests </a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Metabolic Interactions</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Interaction with Alcohol</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Effects on Vasomotor Symptoms </a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Effects on Endometrium</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Effects on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span> or Spotting </a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Women's Health Initiative Studies</a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Women's Health Initiative Memory Study </a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage and Handling</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-17.1" class="toc"></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_13a834b5-e1a5-403c-9169-d1c847d16f73"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">CARDIOVASCULAR DISORDERS</span>, BREAST CANCER, ENDOMETRIAL CANCER and PROBABLE <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">DEMENTIA</span></h1>
<p class="First"><span class="Bold"><span class="Underline">Estrogen Plus Progestin Therapy</span></span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></p>
<p><span class="Bold">Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>, <a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>) and Clinical Studies (<a href="#_Refi4i_section_id_91d543f0-bf67-46ac-91">14.4</a>, <a href="#i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54">14.5</a>)]</span>. </span></p>
<p><span class="Bold">The Women's Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>), and Clinical Studies (<a href="#i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54">14.5</a>)]. </span></span></p>
<p><span class="Bold">The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (</span><a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>) <span class="Italics">, Use in Specific Populations (<a href="#i4i_geriatric_use_id_953cda66-db43-4afe-998c-fc07588263ab">8.5</a>), and Clinical Studies (<a href="#i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54">14.5</a>)].</span>  </span></p>
<p><span class="Bold">Breast Cancer</span></p>
<p><span class="Bold">The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e">5.3</a>), and Clinical Studies (<a href="#_Refi4i_section_id_91d543f0-bf67-46ac-91">14.4</a>)]</span>.</span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. </span></p>
<p><span class="Bold">Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</span></p>
<p><span class="Bold"><span class="Underline">Estrogen-Alone Therapy</span></span></p>
<p><span class="Bold">Endometrial Cancer</span></p>
<p><span class="Bold">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e">5.3</a>)]</span>.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> and Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></span></p>
<p><span class="Bold">Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>, <a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>) and Clinical Studies (<a href="#i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54">14.5</a>,<a href="#i4i_section_id_fc35850c-b450-4195-8cea-40967a7e25cf"> 14.4</a>)].</span></span></p>
<p><span class="Bold">The WHI estrogen-alone substudy reported increased risks of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral CE (0.625 mg)-alone relative to placebo <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>), and Clinical Studies (<a href="#i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54">14.5</a>)].</span></span></p>
<p><span class="Bold">The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>), Use in Specific Populations (<a href="#i4i_geriatric_use_id_953cda66-db43-4afe-998c-fc07588263ab">8.5</a>), and Clinical Studies (<a href="#i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54">14.5</a>)]</span>.</span></p>
<p><span class="Bold">In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other forms of estrogens. Estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_a26248ef-b219-48cc-8328-7be4eb9a7712"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c442810c-392f-489a-beb3-4d9ced29f504"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span> </h2>
<dl>
<dt>•</dt>
<dd>Angeliq 0.25 mg drospirenone (DRSP)/0.5 mg estradiol (E2) is indicated for the treatment of moderate to severe vasomotor symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> in women who have a uterus.</dd>
<dt>•</dt>
<dd>Angeliq 0.5 mg DRSP/1 mg E2 is indicated for the treatment of moderate to severe vasomotor symptoms associated due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> in women who have a uterus.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b13d5922-6a1e-4a4a-9d55-ee4b62a73b7b"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
<dl>
<dt>•</dt>
<dd>Angeliq 0.5 mg DRSP/1 mg E2 is indicated for the treatment of moderate to severe symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> in women who have a uterus. </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_bc95d350-2a7c-4949-9a43-175c92010aa2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Each pack of Angeliq covers 28 days of treatment. Treatment is continuous, which means that the next pack follows immediately without a break. The tablets are to be swallowed whole with some liquid irrespective of food intake and should preferably be taken at the same time every day. In case a tablet is forgotten, it should be taken as soon as possible. If more than 24 hours have elapsed, the missed tablet should not be taken. If several tablets are forgotten, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may occur.</p>
<p>Women who do not take estrogens or women who change from a continuous combination product may start treatment at any time. Women changing from a continuous sequential or cyclic hormone therapy (HT) should complete the current cycle of therapy before initiating Angeliq therapy.</p>
<p>Use of estrogen, alone or in combination with a progestin, should be limited to the lowest effective dose available and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be reevaluated periodically as clinically appropriate to determine if treatment is still necessary <span class="Italics">[see <a href="#id_13a834b5-e1a5-403c-9169-d1c847d16f73">Boxed Warning</a>].</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ecbe5f61-6f73-44ea-a1eb-62e083d437d4"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Treatment of Moderate to Severe Vasomotor Symptoms due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
<p class="First">The dosage is one Angeliq 0.25 mg DRSP/0.5 mg E2 tablet or one Angeliq 0.5 mg DRSP/1 mg E2 tablet taken by mouth once daily. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e2b3ce6b-69b9-4537-9b09-df4d5a2b85d0"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">Atrophy</span> due to <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span></h2>
<p class="First">The dosage is one Angeliq 0.5 mg DRSP/1 mg E2 tablet taken by mouth once daily. </p>
<p>When prescribing solely for the treatment of symptoms of vulvar and vaginal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, topical vaginal products should be considered.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_5d949692-9341-4172-870c-f0862a58dd37"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><span class="Underline">Angeliq 0.25 mg DRSP/0.5 mg E2 Tablets:</span> round, biconvex, yellow, film-coated, embossed with a "EL" inside a hexagon</p>
<p><span class="Underline">Angeliq 0.5 mg DRSP/1 mg E2 Tablets</span>: round, biconvex, pink, film-coated, embossed with a "CK" inside a hexagon</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Do not prescribe Angeliq to women with any of the following conditions: </p>
<dl>
<dt>•</dt>
<dd>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e">5.3</a>)]</span>. </dd>
<dt>•</dt>
<dd>Known, suspected, or history of cancer of the breast<span class="Italics"> [see Warnings and Precautions (<a href="#i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e">5.3</a>)].</span>
</dd>
<dt>•</dt>
<dd>Known or suspected estrogen-dependent neoplasia<span class="Italics"> [see Warnings and Precautions (<a href="#i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e">5.3</a>)].</span>
</dd>
<dt>•</dt>
<dd>Active DVT, PE or history of these conditions <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>)].</span>
</dd>
<dt>•</dt>
<dd>Active arterial thromboembolic disease (for example, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and MI) or history of these conditions <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>)].</span>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a>), Use in Specific Populations (<a href="#i4i_section_id_2e56d5df-209e-4fcd-9861-888710b6a5c7">8.7</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_c0db4322-87bb-4643-bc8d-6027601de7ec">12.3</a>)].</span>
</dd>
<dt>•</dt>
<dd>Known liver impairment or disease <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_ac3343a4-0573-49b0-af06-e2b47e51979d">5.10</a>)</span>,<span class="Italics"> Use in Specific Populations (<a href="#i4i_section_id_888e1bbd-5388-48e6-a14b-4ea4191fca02">8.6</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_c0db4322-87bb-4643-bc8d-6027601de7ec">12.3</a>)]</span>.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal insufficiency</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a>)].</span>
</dd>
<dt>•</dt>
<dd>Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders</dd>
<dt>•</dt>
<dd>Known or suspected pregnancy <span class="Italics">[see Use in Specific Populations (<a href="#i4i_pregnancy_id_025aeb73-b3c3-4d73-9eb1-df9c2a74e4d2">8.1</a>)].</span>
</dd>
<dt>•</dt>
<dd>Known <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Angeliq or any of its ingredients <span class="Italics">[see Adverse Reactions (<a href="#i4i_section_id_44f7e179-f83c-4460-bccc-1ca2a2c87650">6.2</a>)]</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_f139e3a8-72d9-40af-a7b9-4a38bcebc383"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span></h2>
<p class="First">An increased risk of PE, DVT, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and MI have been reported with estrogen plus progestin therapy. An increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and DVT have been reported with estrogen-alone therapy. Should any of these occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately.</p>
<p>Risk factors for arterial vascular disease (for example, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, tobacco use, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, and/or <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>) and/or <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (VTE) [for example, personal history or family history of VTE, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>] should be managed appropriately.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_948307ec-198d-4046-896b-378b227155fd"></a><a name="section-5.1.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </h3>
<p class="First">In the Women's Health Initiative (WHI) estrogen plus progestin substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 50 to 79 years of age receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women in the same age group receiving placebo (33 versus 25 per 10,000 women years) <span class="Italics">[see Clinical Studies (14.4)]</span>. The increase in risk was demonstrated after the first year and persisted.<span class="Sup">1</span> Should a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.</p>
<p>In the WHI estrogen-alone substudy, a statistically significant increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year one and persisted <span class="Italics">[see Clinical Studies (<a href="#_Refi4i_section_id_91d543f0-bf67-46ac-91">14.4</a>)]</span>. Should a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> occur or be suspected, estrogen-alone therapy should be discontinued immediately. </p>
<p>Subgroup analyses of women 50 to 59 years of age suggest no increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> for those women receiving CE (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).<span class="Sup">1</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b22ba409-6ba2-43d0-a957-617bee3cb699"></a><a name="section-5.1.2"></a><p></p>
<h3>Coronary Heart Disease</h3>
<p class="First">In the WHI estrogen plus progestin substudy, there was a statistically non-significant increased risk of coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (41 versus 34 per 10,000 women-years).<span class="Sup">1</span> An increase in relative risk was demonstrated in year 1, and a trend toward decreasing relative risk was reported in years 2 through 5 <span class="Italics">[see Clinical Studies (<a href="#_Refi4i_section_id_91d543f0-bf67-46ac-91">14.4</a>)]</span>.</p>
<p>In the WHI estrogen-alone substudy, no overall effect on CHD events was reported in women receiving estrogen-alone compared to placebo<span class="Sup">2 </span><span class="Italics">[see Clinical Studies (<a href="#_Refi4i_section_id_91d543f0-bf67-46ac-91">14.4</a>)]</span>.</p>
<p>Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE 0.625 mg compared to placebo) in women with less than 10 years since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (8 versus 16 per 10,000 women-years).<span class="Sup">1</span></p>
<p>In postmenopausal women with documented heart disease (n=2,763), average 66.7 years of age, in a controlled clinical trial of secondary prevention of cardiovascular disease (Heart and Estrogen/Progestin Replacement Study [HERS]), treatment with daily CE (0.625 mg) plus MPA (2.5 mg) demonstrated no cardiovascular benefit. During an average follow-up of 4.1 years, treatment with CE plus MPA did not reduce the overall rate of CHD events in postmenopausal women with established CHD. There were more CHD events in the CE plus MPA-treated group than in the placebo group in year 1, but not during the subsequent years. Two thousand, three hundred and twenty-one (2,321) women from the original HERS trial agreed to participate in an open label extension of HERS, HERS II. Average follow-up in HERS II was an additional 2.7 years, for a total of 6.8 years overall. Rates of CHD events were comparable among women in the CE plus MPA group and the placebo group in HERS, HERS II, and overall. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a7e37d4-58b9-4de3-a706-2f73c7c8aaeb"></a><a name="section-5.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">Venous Thromboembolism</span> </h3>
<p class="First">In the WHI estrogen plus progestin substudy, a statistically significant 2-fold greater rate of VTE (DVT and PE) was reported in women receiving daily CE (0.625 mg) plus MPA (2.5 mg) compared to women receiving placebo (35 versus 17 per 10,000 women-years). Statistically significant increases in risk for both DVT (26 versus 13 per 10,000 women-years) and PE (18 versus 8 per 10,000 women-years) were also demonstrated. The increase in VTE risk was demonstrated during the first year and persisted<span class="Sup">3 </span><span class="Italics">[see Clinical Studies (<a href="#_Refi4i_section_id_91d543f0-bf67-46ac-91">14.4</a>)]</span>. Should a VTE occur or be suspected, estrogen plus progestin therapy should be discontinued immediately.</p>
<p>In the WHI estrogen-alone substudy, the risk of VTE was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years<span class="Sup">4 </span><span class="Italics">[see Clinical Studies (<a href="#_Refi4i_section_id_91d543f0-bf67-46ac-91">14.4</a>)]</span>. Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately. </p>
<p>If feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, or during periods of prolonged immobilization. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">Angeliq contains the progestin DRSP that has antialdosterone activity, including the potential for <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> in high-risk patients. Angeliq is contraindicated in patients with conditions that predispose to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, and <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>).</p>
<p style="border-left:1px solid;">Use caution when prescribing Angeliq to women who regularly take other medications that can increase potassium, such as non-steroidal anti-inflammatory drugs (NSAIDs), potassium-sparing diuretics, potassium supplements, angiotensin converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists, heparin and aldosterone antagonists. <span class="XmChange">Consider monitoring serum potassium concentrations during the first month of dosing in high-risk patients who take strong CYP3A4 inhibitors long-term and concomitantly. Strong CYP3A4 inhibitors include azole antifungals (for example, ketoconazole, itraconazole, voriconazole), human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV)/<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus (HCV) protease inhibitors (for example, indinavir, boceprevir), and clarithromycin <span class="Italics">[see Drug Interactions (<a href="#i4i_section_id_89709cc7-b783-4ecb-b0d8-34ade23dee53">7.1</a>) and Clinical Pharmacology </span></span><span class="Italics">(<a href="#i4i_pharmacokinetics_id_c0db4322-87bb-4643-bc8d-6027601de7ec">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Malignant Neoplasms </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_897af1a1-a68c-41f8-b3b3-7f46b46b44b1"></a><a name="section-5.3.1"></a><p></p>
<h3>Breast Cancer </h3>
<p class="First">The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg). After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of breast cancer in women who took daily CE plus MPA. In this substudy, prior use of estrogen-alone or estrogen plus progestin therapy was reported by 26 percent of the women. The relative risk of invasive breast cancer was 1.24 and the absolute risk was 41 versus 33 cases per 10,000 women-years, for CE plus MPA compared with placebo. Among women who reported prior use of hormone therapy, the relative risk of invasive breast cancer was 1.86 and the absolute risk was 46 versus 25 cases per 10,000 women-years for CE plus MPA compared with placebo. Among women who reported no prior use of hormone therapy, the relative risk of invasive breast cancer was 1.09 and the absolute risk was 40 versus 36 cases per 10,000 women-years for CE plus MPA compared with placebo. In the same substudy, invasive breast cancers were larger, were more likely to be node positive, and were diagnosed at a more advanced stage in the CE (0.625 mg) plus MPA (2.5 mg) group compared with the placebo group. <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">Metastatic disease</span> was rare, with no apparent difference between the two groups. Other prognostic factors, such as histologic subtype, grade and hormone receptor status did not differ between the groups<span class="Sup">5 </span><span class="Italics">[see Clinical Studies (<a href="#_Refi4i_section_id_91d543f0-bf67-46ac-91">14.4</a>)].</span></p>
<p>The most important randomized clinical trial providing information about breast cancer in estrogen-alone users is the WHI substudy of daily CE (0.625 mg)-alone. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE (0.625 mg)-alone was not associated with an increased risk of invasive breast cancer [relative risk <span class="Italics">[see Clinical Studies (<a href="#_Refi4i_section_id_91d543f0-bf67-46ac-91">14.4</a>)]</span>. </p>
<p>Consistent with the WHI clinical trial, observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy, and a smaller increased risk for estrogen-alone therapy, after several years of use. The risk increased with duration of use, and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). Observational studies also suggest that the risk of breast cancer was greater, and became apparent earlier, with estrogen plus progestin therapy as compared to estrogen-alone therapy. However, these studies have not generally found significant variation in the risk of breast cancer among different estrogen plus progestin combinations, doses, or routes of administration.</p>
<p>The use of estrogen-alone and estrogen plus progestin has been reported to result in an increase in abnormal mammograms requiring further evaluation. </p>
<p>All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_405abd07-934c-4910-836d-22a7a8d2fc13"></a><a name="section-5.3.2"></a><p></p>
<h3>Endometrial Cancer </h3>
<p class="First">An increased risk of endometrial cancer has been reported with the use of unopposed estrogen therapy in a woman with a uterus. The reported endometrial cancer risk among unopposed estrogen users is about 2- to 12-fold greater than in non-users, and appears dependent on duration of treatment and on estrogen dose. Most studies show no significant increased risk associated with use of estrogens for less than 1 year. The greatest risk appears associated with prolonged use, with increased risks of 15- to 24-fold for 5 to 10 years or more. This risk has been shown to persist for at least 8 to 15 years after estrogen therapy is discontinued. </p>
<p>Clinical surveillance of all women using estrogen-alone or estrogen plus progestin therapy is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </p>
<p>There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens of equivalent estrogen dose. Adding a progestin to estrogen therapy in postmenopausal women has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span>, which may be a precursor to endometrial cancer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6f4c41ea-53e8-4216-815b-593e79c16abc"></a><a name="section-5.3.3"></a><p></p>
<h3>Ovarian Cancer </h3>
<p class="First">The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent CI 0.77-3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years.<span class="Sup">7</span> In some epidemiological studies, the use of estrogen plus progestin and estrogen-only products, in particular for 5 or more years, has been associated with an increased risk of ovarian cancer. However, the duration of exposure associated with increased risk is not consistent across all epidemiologic studies and some report no association.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span></h2>
<p class="First">In the Women’s Health Initiative Memory Study (WHIMS) estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>.  The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years<span class="Sup">8</span><span class="Italics"> [see Use in Specific Populations (<a href="#i4i_geriatric_use_id_953cda66-db43-4afe-998c-fc07588263ab">8.5</a>), and Clinical Studies (<a href="#i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54">14.5</a>)]</span>.</p>
<p>In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. The relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years<span class="Sup">8</span><span class="Italics"> [see Use in Specific Populations (<a href="#i4i_geriatric_use_id_953cda66-db43-4afe-998c-fc07588263ab">8.5</a>) and Clinical Studies (<a href="#i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54">14.5</a>)].</span></p>
<p>When data from the two populations in the WHIMS estrogen-alone and estrogen plus progestin ancillary studies were pooled as planned in the WHIMS protocol, the reported overall relative risk for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 percent CI 1.19-2.60). Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women<span class="Sup">8</span><span class="Italics"> [see Use in Specific Populations (<a href="#i4i_geriatric_use_id_953cda66-db43-4afe-998c-fc07588263ab">8.5</a>) and Clinical Studies (<a href="#i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54">14.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_02a9753d-3e85-4d47-954f-30ed78cb9d9f"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder Disease</span> </h2>
<p class="First">A 2- to 4-fold increase in the risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> requiring surgery in postmenopausal women receiving estrogens has been reported. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7dab8756-4e5a-4e15-ab39-e13d83cdbf7b"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> </h2>
<p class="First">Estrogen administration may lead to severe <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> in women with breast cancer and bone <span class="product-label-link" type="condition" conceptid="432851" conceptname="Secondary malignant neoplastic disease">metastases</span>. If <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> occurs, use of the drug should be stopped and appropriate measures taken to reduce the serum calcium concentration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7b576ab6-a487-4b1e-a241-8faef65e475c"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Visual Abnormalities </h2>
<p class="First">Retinal vascular <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> has been reported in women receiving estrogens. Discontinue medication pending examination if there is sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, or a sudden onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, or <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>. If examination reveals <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> or retinal vascular lesions, estrogens should be permanently discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27473455-5c36-4d25-8391-a595b60139e6"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Elevated Blood Pressure </h2>
<p class="First">In a small number of case reports, substantial increases in blood pressure have been attributed to idiosyncratic reactions to estrogens. In a large, randomized, placebo-controlled clinical trial, a generalized effect of estrogen therapy on blood pressure was not seen. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c149f4e-413e-4afb-86f9-ead7215a3ad1"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span> </h2>
<p class="First">In women with pre-existing <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, estrogen therapy may be associated with elevations of plasma triglycerides leading to <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>. Consider discontinuation of treatment if <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac3343a4-0573-49b0-af06-e2b47e51979d"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> and/or Past History of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic Jaundice</span> </h2>
<p class="First">Estrogens may be poorly metabolized in women with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>. For women with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> associated with past estrogen use or with pregnancy, caution should be exercised and in the case of recurrence, medication should be discontinued. </p>
<p>The clearance of drospirenone was decreased in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f43a3bbe-5b99-4f41-abfc-472f05135718"></a><a name="section-5.11"></a><p></p>
<h2>5.11 <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span> </h2>
<p class="First">Estrogen administration leads to increased thyroid-binding globulin (TBG) concentrations. Women with <span class="product-label-link" type="condition" conceptid="4193309" conceptname="Thyroid function tests normal">normal thyroid function</span> can compensate for the increased TBG by making more thyroid hormone, thus maintaining free T<span class="Sub">4</span> and T<span class="Sub">3</span> serum concentrations in the normal range. Women dependent on thyroid hormone replacement therapy who are also receiving estrogens may require increased doses of their thyroid replacement therapy. These women should have their thyroid function monitored in order to maintain their free thyroid hormone concentrations in an acceptable range. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4b0316e7-2c70-443d-bd66-d6872ccbece8"></a><a name="section-5.12"></a><p></p>
<h2>5.12 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span> </h2>
<p class="First">Estrogens and progestins may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. Women with conditions that might be influenced by this factor, such as a cardiac or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, warrant careful observation when estrogens are prescribed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b37d9bc-6ce9-4cb0-86c2-c729ffc1c95f"></a><a name="section-5.13"></a><p></p>
<h2>5.13 <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> </h2>
<p class="First">Estrogen therapy should be used with caution in women with <span class="product-label-link" type="condition" conceptid="140362" conceptname="Hypoparathyroidism">hypoparathyroidism</span> as estrogen-induced <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> may occur. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_29e65de2-0fd2-4594-8829-ed438379347b"></a><a name="section-5.14"></a><p></p>
<h2>5.14 <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> </h2>
<p class="First">As an aldosterone antagonist, drospirenone may increase the possibility of <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> in high-risk patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c902e1c7-0a21-4779-b757-038a8da6a9f2"></a><a name="section-5.15"></a><p></p>
<h2>5.15 Exacerbation of <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> </h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">Endometriosis</span> may be exacerbated with administration of estrogens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9dfdb514-1ead-408f-a2ff-98c79d49af56"></a><a name="section-5.16"></a><p></p>
<h2>5.16 <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">Hereditary Angioedema</span></h2>
<p class="First">Exogenous estrogens may exacerbate symptoms of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in women with <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">hereditary angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_17c19f3c-86df-4bb4-85ce-acadfa857de2"></a><a name="section-5.17"></a><p></p>
<h2>5.17 Exacerbation of Other Conditions </h2>
<p class="First">Estrogen therapy may cause an <span class="product-label-link" type="condition" conceptid="257581" conceptname="Exacerbation of asthma">exacerbation of asthma</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> <span class="product-label-link" type="condition" conceptid="439035" conceptname="Otosclerosis">otosclerosis</span>, <span class="product-label-link" type="condition" conceptid="440990" conceptname="Chorea">chorea</span> minor and hepatic <span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> and should be used with caution in women with these conditions. In women with <span class="product-label-link" type="condition" conceptid="4307793" conceptname="Hereditary angioedema">hereditary angioedema</span> exogenous estrogens may induce or exacerbate symptoms of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4b0e09bc-07b4-4411-945f-33a64d03d797"></a><a name="section-5.18"></a><p></p>
<h2>5.18 Laboratory Tests </h2>
<p class="First">Serum follicle stimulating hormone (FSH) and estradiol concentrations have not been shown to be useful in the management of moderate to severe vasomotor symptoms. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e96d0a31-ae9e-43c1-87c9-304133e9547d"></a><a name="section-5.19"></a><p></p>
<h2>5.19 Interference with Laboratory Tests </h2>
<p class="First">Accelerated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII–X complex, II–VII–X complex, and beta-thromboglobulin; decreased concentrations of anti-factor Xa and antithrombin III, decreased antithrombin III activity; increased concentrations of fibrinogen and fibrinogen activity; increased <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> antigen and activity. </p>
<p>Increased TBG concentrations leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T<span class="Sub">4</span> concentrations (by column or by radioimmunoassay) or T<span class="Sub">3</span> concentrations by radioimmunoassay. T<span class="Sub">3</span> resin uptake is decreased, reflecting the elevated TBG. Free T<span class="Sub">4</span> and free T<span class="Sub">3</span> concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone. </p>
<p>Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span>, leading to increased total circulating corticosteroids and sex steroids, respectively. Free hormone concentrations, such as testosterone and estradiol, may be decreased. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-l-antitrypsin, <span class="product-label-link" type="condition" conceptid="4294533" conceptname="Ferroxidase">ceruloplasmin</span>). </p>
<p>Increased plasma high-density lipoprotein (HDL) and HDL<span class="Sub">2</span> subfraction concentrations, reduced low-density lipoprotein (LDL) <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> concentration, increased triglyceride concentrations. </p>
<p>Impaired glucose tolerance. </p>
<p>Reduced response to metyrapone test.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_ec492380-a609-4027-b046-ade2642a0b5f"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span> <span class="Italics">[see Boxed Warning, and Warnings and Precautions (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>)]</span>
</dd>
<dt>•</dt>
<dd>Malignant Neoplasms <span class="Italics">[see Boxed Warning, and Warnings and Precautions (<a href="#i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e">5.3</a>)]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a37b7ef-24f2-4433-93ea-e47f7fa881fc"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </p>
<p>From clinical trials with different dose formulations of Angeliq containing E2 dose ranging from 0.5 mg to 1.0 mg combined with DRSP dose ranging from 0.25 mg to 3 mg:</p>
<dl>
<dt>•</dt>
<dd>The most common adverse reactions were gastrointestinal and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, female genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. The frequencies of common adverse reactions, in general, were higher for the Angeliq dose formulation containing E2 1 mg compared to Angeliq containing E2 0.5 mg.</dd>
<dt>•</dt>
<dd>The most common adverse reactions leading to drug discontinuation in controlled clinical trials were <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="195321" conceptname="Postmenopausal bleeding">postmenopausal bleeding</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increased</span>.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_313fdc52-1e9c-4613-9f89-316efde56dac"></a><a name="section-6.1.1"></a><p></p>
<h3>Placebo-Controlled Trial:</h3>
<p class="First">In a placebo-controlled trial evaluating Angeliq 0.25 mg DRSP/0.5 mg E2, 183 postmenopausal women received at least one dose of DRSP 0.25 mg/0.5 mg E2 and 180 received placebo. Study subjects were treated for 3 cycles of 28 days each for a total of 12 weeks of treatment. The median age was 53 years (range: 40-77 years) and over 50% of subjects had a hysterectomy, 68% were Caucasian and 24% were Black. Table 1 summarizes adverse reactions reported in at least 2% of subjects receiving Angeliq 0.25 mg DRS/0.5 mg E2 and at a higher incidence than subjects receiving placebo.</p>
<a name="_Refid_0f9aca08-d74c-48d2-8ba4-14315cce1"></a><table width="100%">
<caption><span>Table 1: Adverse Reactions that Occurred at a Frequency of ≥ 2% with Angeliq 0.25 mg DRSP/0.5 mg E2 and at a higher incidence than placebo</span></caption>
<col width="40%">
<col width="31%">
<col width="30%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Gastrointestinal and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> includes: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (overall, lower, and upper), <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="197981" conceptname="Abdominal tenderness">abdominal tenderness</span></dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span> includes: <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="4021485" conceptname="Nipple tenderness">nipple pain</span></dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" valign="top"><p class="First">Adverse Reaction</p></td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First">Angeliq</p>
<p>(0.25 mg DRSP/0.5 mg E2)<br>N=183 (100%)</p>
<p>n (%)</p>
</td>
<td class="Botrule Toprule" align="center" valign="top">
<p class="First">Placebo <br>N=180 (100%)</p>
<p>n (%)</p>
</td>
</tr>
<tr>
<td valign="top"><p class="First">Gastrointestinal and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pains</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td align="center" valign="top"><p class="First">11  (6.0)</p></td>
<td align="center" valign="top"><p class="First">5  (2.8)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td align="center" valign="top"><p class="First">11  (6.0)</p></td>
<td align="center" valign="top"><p class="First">9  (5.0)</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Vulvovaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span></p></td>
<td align="center" valign="top"><p class="First">10  (5.5)</p></td>
<td align="center" valign="top"><p class="First">1  (0.6)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td align="center" valign="top"><p class="First">6  (3.3)</p></td>
<td align="center" valign="top"><p class="First">1  (0.6)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </p></td>
<td align="center" valign="top"><p class="First">6  (3.3)</p></td>
<td align="center" valign="top"><p class="First">2  (1.1)</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </p></td>
<td align="center" valign="top"><p class="First">4   2.2)</p></td>
<td align="center" valign="top"><p class="First">1  (0.6)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral Edema</span> </p></td>
<td class="Botrule" align="center" valign="top"><p class="First">4  (2.2)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">2  (1.1)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f2639a03-286d-407f-8b20-12e85df09a66"></a><a name="section-6.1.2"></a><p></p>
<h3>Pooled data of clinical trials with different dose formulations of Angeliq:</h3>
<p class="First">Data from 13 clinical trials in postmenopausal subjects treated with different dose formulations of Angeliq containing 1 mg E2 (1 mg E2 + 0.5 mg – 3.0 mg DRSP; N=2842) were pooled to provide an overall estimate of adverse reactions. Similarly, data from 2 clinical trials with Angeliq containing 0.5 mg E2 (0.5 mg E2 + DRSP 0.25 mg – 0.5 mg; N=853) were pooled for the same purpose. Table 2 shows adverse reactions reported in at least 1% of subjects treated with Angeliq.</p>
<a name="_Refid_8b6fb6c8-9ec8-4558-b905-712a95363"></a><table width="100%">
<caption><span>Table 2: Adverse Reactions that Occurred at a Frequency of ≥ 1% in Clinical Trials</span></caption>
<col width="28%">
<col width="36%">
<col width="37%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Adverse Reaction</span></p></td>
<td class="Botrule Rrule Toprule" valign="top">
<p class="First">Angeliq containing 1 mg E2 </p>
<p>N = 2842</p>
<p>n (%)</p>
</td>
<td class="Botrule Rrule Toprule" valign="top">
<p class="First">Angeliq containing 0.5 mg E2 </p>
<p>N=853</p>
<p>n (%)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">508 (17.9)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">53 (6.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Female genital tract <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">397 (14.0)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">21 (2.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Gastrointestinal and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">186 (6.5)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">31 (3.6)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="199877" conceptname="Mucous polyp of cervix">Cervical polyp</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">34 (1.2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">3 (0.4)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional lability</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">35 (1.2)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11 (1.3)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">28 (1.0)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">5 (0.6)</p></td>
</tr>
</tbody>
</table>
<p>Adverse Reactions in clinical studies were coded using the MedDRA dictionary (version 13.0). Different MedDRA terms representing the same medical phenomenon have been grouped together as single adverse reactions to avoid diluting or obscuring the true effect.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_44f7e179-f83c-4460-bccc-1ca2a2c87650"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following additional adverse reactions have been reported during post approval use of Angeliq. Because these reactions are reported voluntarily from a population of uncertain size, reliably estimating their frequency or establishing a causal relationship to drug exposure is not always possible.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, pruritis, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Italics">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span></span>: Breast cancer</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span>: venous and arterial <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (peripheral deep <span class="product-label-link" type="condition" conceptid="4145867" conceptname="Venous occlusion">venous occlusion</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>/pulmonary <span class="product-label-link" type="condition" conceptid="4093906" conceptname="Obstruction">vascular occlusion</span>, <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>/<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>/<span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> not specified as hemorrhagic)</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_2a90afa9-474b-4481-a452-69dd06a29b62"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">No formal drug-drug interaction studies have been conducted for Angeliq.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_89709cc7-b783-4ecb-b0d8-34ade23dee53"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Metabolic Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49026f87-cc82-4622-9b37-2d46b1742e75"></a><a name="section-7.1.1"></a><p></p>
<h3>Effect of Drospirenone on Other Drugs</h3>
<p class="First">The potential effect of DRSP on CYP2C19 activity was investigated in a clinical pharmacokinetic study using omeprazole as a marker substrate. No significant effect of DRSP on the systemic clearance of the CYP3A4 product omeprazole sulfone was found. These results demonstrated that DRSP did not inhibit CYP2C19 and CYP3A4 <span class="Italics">in vivo</span>. Two further clinical drug-drug interaction studies using simvastatin and midazolam as marker substrates for CYP3A4, respectively, were performed and the results of these studies demonstrated that pharmacokinetics of the CYP3A4 substrates were not influenced by steady-state DRSP concentrations.</p>
<p>Co-administration of DRSP and drugs that may increase serum potassium: There is a potential for an increase in serum potassium in women taking DRSP with other drugs that may affect electrolytes, such as ACE inhibitors, angiotensin receptor blockers, or NSAIDs, more pronounced in diabetic women <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a>), and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_c0db4322-87bb-4643-bc8d-6027601de7ec">12.3</a>)]</span>. </p>
<p>Electrolytes were studied in postmenopausal women with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and/or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus requiring an ACE inhibitor or angiotensin receptor blocker. After 28 days of exposure to 1 mg E2 and 3 mg DRSP (n=112) or placebo (n=118). The mean change from baseline in serum potassium was 0.11 mEq/L for the E2/DRSP group and 0.08 mEq/L for the placebo group. None of the subjects with serum potassium concentrations ≥5.5 mEq/L had cardiovascular adverse events. </p>
<p>A drug-drug interaction study of DRSP 3 mg/E2 1 mg versus placebo was performed in mildly hypertensive postmenopausal women taking enalapril maleate 10 mg twice daily. Potassium concentrations were obtained every other day for a total of 2 weeks in all subjects. Mean serum potassium concentrations in the DRSP/E2 treatment group relative to baseline were 0.22 mEq/L higher than those in the placebo group. On Day 14, the ratios for serum potassium C<span class="Sub">max</span> and AUC in the DRSP/E2 group to those in the placebo group were 0.955 (90% CI: 0.914, 0.999) and 1.01 (90% CI: 0.944, 1.08), respectively. No patient in either treatment group developed <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium concentrations &gt;5.5 mEq/L). </p>
<p>Of note, occasional or chronic use of NSAID medication was not restricted in any of the Angeliq clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_96abc645-97cb-49df-86c1-4b1b1f093c66"></a><a name="section-7.1.2"></a><p></p>
<h3>Effect of Other Drugs on Estrogens and Progestins</h3>
<p class="First"><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies have shown that estrogens and progestins are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. In a clinical drug-drug interaction study conducted in premenopausal women, once daily co-administration of DRSP 3 mg/E2 1.5 mg containing tablets with strong CYP3A4 inhibitor, ketoconazole 200 mg twice daily for 10 days resulted in a moderate increase of exposure and a mild increase of peak concentration for DRSP. The E2 exposure and peak concentration were unaffected by ketoconazole, although the exposure and peak concentration of estrone (E1) increased. Although no clinically relevant effects on any safety or laboratory parameters including serum potassium were observed, this study only assessed subjects for 10 days. The clinical impact for a woman taking a DRSP-containing combination hormone and chronic use of a CYP3A4/5 inhibitor is unknown.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fb1bee39-0f72-453e-8afe-163faabcbb62"></a><a name="section-7.1.2.1"></a><p></p>
<h4>Substances decreasing the exposure and possibly diminishing the efficacy of estrogens and progestins (enzyme inducers)  </h4>
<p class="First">Inducers of CYP3A4 such as St. John's wort (<span class="Italics">Hypericum perforatum</span>), phenobarbital, carbamazepine, and rifampin may reduce plasma concentrations of estrogens and progestins, possibly resulting in a decrease in therapeutic effects and/or changes in the <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> profile.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_71ffaf01-4fce-46cb-943f-2378cdaced33"></a><a name="section-7.1.2.2"></a><p></p>
<h4>Substances increasing the exposure of estrogens and progestins (enzyme inhibitors)  </h4>
<p class="First">Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (for example, ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (for example, clarithromycin, erythromycin), diltiazem, and grapefruit juice did increase the plasma concentrations of the estrogen or the progestin or both <span class="Italics">[see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_490867fd-685a-45a0-a439-47ecad3d5ed7"></a><a name="section-7.1.2.3"></a><p></p>
<h4>HIV/HCV protease inhibitors and non-nucleoside reverse transcriptase inhibitors  </h4>
<p class="First">Significant changes (increase or decrease) in the plasma concentrations of estrogen and progestin have been noted in some cases of co-administration with HIV/HCV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8b8cf208-c9da-49ca-8115-180473a3eec0"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Interaction with Alcohol</h2>
<p class="First">Acute alcohol ingestion during use of hormone therapy may lead to elevations of circulating E2 concentrations.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_aa8468c8-f852-47c9-aa5d-f502bff12bb6"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_025aeb73-b3c3-4d73-9eb1-df9c2a74e4d2"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Angeliq should not be used during pregnancy <span class="Italics">[see Contraindications (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>)].</span> There appears to be little or no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_67f1c69f-114e-44e1-a777-ae01523f3ac1"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Angeliq should not be used during lactation. Estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. Detectable amounts of estrogens have been identified in the milk of women receiving estrogen. Caution should be exercised when Angeliq is administered to a nursing woman.</p>
<p>After administration of an oral contraceptive containing DRSP about 0.02% of the DRSP dose was excreted into the breast milk of postpartum women within 24 hours. This results in a maximal daily dose of about 3 mcg DRSP in an infant.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_192bb5ee-086e-4c3a-878f-4ad7a1e79a05"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Angeliq is not indicated in children. Clinical studies have not been conducted in the pediatric populations.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_953cda66-db43-4afe-998c-fc07588263ab"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There have not been sufficient numbers of geriatric women involved in clinical studies utilizing Angeliq to determine whether those over 65 years of age differ from younger women in their response to Angeliq. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f176cde7-94fc-47ee-8bee-d87c35f78298"></a><a name="section-8.4.1"></a><p></p>
<h3>The Women’s Health Initiative Studies</h3>
<p class="First">In the WHI estrogen plus progestin substudy (daily CE [0.625 mg] plus MPA [2.5 mg] versus placebo), there was a higher relative risk of nonfatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and invasive breast cancer in women greater than 65 years of age <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>, <a href="#i4i_section_id_3c0197a0-fff7-4da1-8ead-75b6a387ae3e">5.3</a>) and Clinical Studies (<a href="#_Refi4i_section_id_91d543f0-bf67-46ac-91">14.4</a>)]</span>.</p>
<p>In the WHI estrogen-alone substudy (daily CE [0.625 mg] versus placebo), there was a higher relative risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in women greater than 65 years of age <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_bdcb6535-1380-422e-aa77-919863d0dc13">5.1</a>)and Clinical Studies (<a href="#_Refi4i_section_id_91d543f0-bf67-46ac-91">14.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c2f42057-9cc2-41ca-9fdd-c1f3acefe9b4"></a><a name="section-8.4.2"></a><p></p>
<h3>The Women’s Health Initiative Memory Study</h3>
<p class="First">In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in women receiving estrogen plus progestin or estrogen-alone when compared to placebo <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>), and Clinical Studies (<a href="#i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54">14.5</a>)]</span>.</p>
<p>Since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women<span class="Sup">8 </span><span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>), and Clinical Studies (<a href="#i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54">14.5</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_888e1bbd-5388-48e6-a14b-4ea4191fca02"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Angeliq is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> because of the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> <span class="Italics">[see Contraindications (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>), Warnings and Precautions (<a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a></span><span class="Underline">) </span><span class="Italics"> and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_c0db4322-87bb-4643-bc8d-6027601de7ec">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e56d5df-209e-4fcd-9861-888710b6a5c7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Angeliq is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> because of the risk of increased DRSP exposure and subsequent <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> <span class="Italics">[see Contraindications (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>), Warnings and Precautions (<a href="#i4i_section_id_ac3343a4-0573-49b0-af06-e2b47e51979d">5.10</a>)</span><span class="Underline"> </span><span class="Italics"> and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_c0db4322-87bb-4643-bc8d-6027601de7ec">12.3</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_60b69801-6769-4ba6-9e8f-8f84e2dd6ba6"></a><a name="section-8.7"></a><p></p>
<h2>8.8 <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span></h2>
<p class="First">Angeliq is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> because of the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> <span class="Italics">[see Contraindications (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>) and Warnings and Precautions (<a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_ee456600-9f48-4bbe-b586-50c87b7c6e0a"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage of estrogen plus progestin may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in women. Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> consists of discontinuation of Angeliq therapy with institution of appropriate symptomatic care.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_44a0a2ab-5846-4b07-a0df-dcce0bf7caed"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Angeliq tablets, for oral administration, provide a hormone regimen consisting of drospirenone and estradiol. </p>
<p>Drospirenone, (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3´,4´,6, 6a,7,8,9,10,11,12,13,14,15,15a,16-hexadecahydro-10,13-dimethylspiro-[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene- 17,2´(5H)-furan]-3,5´(2H)-dione (CAS) is a synthetic progestational compound and has a molecular weight of 366.5 and a molecular formula of C<span class="Sub">24</span>H<span class="Sub">30</span>O<span class="Sub">3</span>. </p>
<p>Estradiol USP, (Estra-1,3,5(10)-triene-3,17-diol,17ß), has a molecular weight of 272.39 and the molecular formula is C<span class="Sub">18</span>H<span class="Sub">24</span>O<span class="Sub">2</span>. The structural formulas are as follows:</p>
<div class="Figure">
<a name="id1441"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=761834c2-6b61-4583-84c2-f1ca4a97c4f2&amp;name=image-01.jpg">
</div>
<p>The inactive ingredients in Angeliq 0.5 mg DRSP/1 mg E2 tablets are: lactose monohydrate NF, corn starch NF, pregelatinized starch NF, povidone 25000 USP, magnesium stearate NF, hydroxylpropylmethyl cellulose USP, macrogol 6000 NF, talc USP, titanium dioxide USP, and red ferric oxide pigment NF.</p>
<p>The inactive ingredients in Angeliq 0.25 mg DRSP/0.5 mg E2 tablets are: lactose monohydrate NF, corn starch NF, pregelatinized starch NF, povidone 25000 USP, magnesium stearate NF, hydroxylpropylmethyl cellulose USP, macrogol 6000 NF, talc USP, titanium dioxide USP, and yellow ferric oxide pigment NF. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_bd3d405c-a66d-44c7-89c7-0d860fef3f01"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_c6574ab5-0441-441e-aa0b-99b4c66113ad"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol (E2) is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. </p>
<p>The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate-conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women.</p>
<p>Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, 2 estrogen receptors have been identified. These will</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_d84a9598-3303-477d-99fc-f0cb0f843f06"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">No clinical pharmacology studies have been conducted for Angeliq.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_c0db4322-87bb-4643-bc8d-6027601de7ec"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9c416723-5a28-42da-a246-1782e0b0d512"></a><a name="section-11.3.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Serum concentrations of DRSP reach peak concentrations approximately 1 hour after administration of Angeliq and mean absolute bioavailability of DRSP ranges from 76–85%. Following oral administration, the median T<span class="Sub">max</span> of serum estradiol was approximately 2 hours after dosing with Angeliq and T<span class="Sub">max</span> ranged between 0.3-10 hours. </p>
<p>The pharmacokinetics of DRSP are dose proportional within the dose range of 0.25–4 mg. Following daily dosing of Angeliq, steady state DRSP concentrations were observed after 10 days. Mean accumulation ratios for DRSP and estradiol were 2.3 and 2.0, respectively, following multiple doses of 0.5 mg DRSP/1 mg E2, and 2.6 and 1.6, respectively, following multiple doses of 0.25 mg DRSP/0.5 mg E2. Mean concentrations at 2 hours for DRSP ranged between 5.9 and 6.7 ng/mL after treatment with Angeliq (0.5 mg DRSP/1 mg E2) for 365 days. Mean steady state serum DRSP and E2 concentrations are shown in Figure 1, and a summary of primary pharmacokinetic parameters following the administration of 0.25 mg DRSP/0.5 mg E2 or 0.5 mg DRSP/1 mg E2 at steady state is presented in Table 3.</p>
<div class="Figure">
<a name="id1489"></a><img alt="Figuree 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=761834c2-6b61-4583-84c2-f1ca4a97c4f2&amp;name=image-02.jpg"><p class="MultiMediaCaption">Figure 1: Mean (± SD) steady state serum drospirenone and estradiol concentrations following daily oral administration of  0.25 or 0.5 mg Drospirenone and 0.5 or 1 mg Estradiol</p>
</div>
<a name="_Refid_1cf264ef-54d3-4934-ab52-786fe14f2"></a><table width="100%">
<caption><span>Table 3: Mean (± SD) Steady State Pharmacokinetic Parameters after Administration of Tablets  Containing 0.25 or 0.5 mg Drospirenone and 0.5 or 1 mg Estradiol </span></caption>
<col width="22%">
<col width="18%">
<col width="28%">
<col width="32%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>N=16</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Unit</span></p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">0.25 mg DRSP/0.5 mg E2</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">0.5 mg DRSP/1 mg E2</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" colspan="2" valign="top"><p class="First"><span class="Bold">Drospirenone (DRSP)</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">N=12</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">N=17</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">C<span class="Sub">max</span></p></td>
<td align="center" valign="top"><p class="First">ng/mL</p></td>
<td align="center" valign="top"><p class="First">5.70 (1.42)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">8.50 (1.63)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">T<span class="Sub">max</span></p></td>
<td align="center" valign="top"><p class="First">h</p></td>
<td align="center" valign="top"><p class="First">0.992 (0.667 – 1.03)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">1.02 (1 – 2.03)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">AUC (0-24)</p></td>
<td align="center" valign="top"><p class="First">ng·h/mL</p></td>
<td align="center" valign="top"><p class="First">48.5 (13.7)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">84.3 (19.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">t<span class="Sub">1/2</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">h</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">N/A</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">39.2<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>(8.5)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4" valign="top"><p class="First"><span class="Bold">Estradiol (E2)</span></p></td></tr>
<tr>
<td class="Lrule" valign="top"><p class="First">C<span class="Sub">max</span></p></td>
<td align="center" valign="top"><p class="First">pg/mL</p></td>
<td align="center" valign="top"><p class="First">29.7 (6.80)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">63.7 (24.2)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">T<span class="Sub">max</span></p></td>
<td align="center" valign="top"><p class="First">h</p></td>
<td align="center" valign="top"><p class="First">2.33 (0.32 – 10)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">2.01 (0.5 – 6.02)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">AUC (0-24)</p></td>
<td align="center" valign="top"><p class="First">pg·h/mL</p></td>
<td align="center" valign="top"><p class="First">515.4 (142.0)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">882 (267)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">t<span class="Sub">1/2</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">h</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">N/A</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">20.5 (2.67)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="4" valign="top"><p class="First"><span class="Bold">Estrone (E1)</span></p></td></tr>
<tr>
<td class="Lrule" valign="top"><p class="First">C<span class="Sub">max</span></p></td>
<td align="center" valign="top"><p class="First">pg/mL</p></td>
<td align="center" valign="top"><p class="First">165.7 (40.4)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">362 (122)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">T<span class="Sub">max</span></p></td>
<td align="center" valign="top"><p class="First">h</p></td>
<td align="center" valign="top"><p class="First">3.98 (1.98 – 7.05)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">6 (3.99 – 10)</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">AUC (0-24)</p></td>
<td align="center" valign="top"><p class="First">pg·h/mL</p></td>
<td align="center" valign="top"><p class="First">2839 (658)</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">5561 (1689)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">t<span class="Sub">1/2</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">h</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">N/A</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">19.9 (2.10)</p></td>
</tr>
</tbody>
</table>
<p>Except for T<span class="Sub">max</span>, the mean PK results of DRSP, E2, and E1 are displayed as the arithmetic mean and standard deviation (SD, in parentheses). For T<span class="Sub">max</span> the median and range are provided.</p>
<p>C<span class="Sub">max</span>=Maximum observed serum concentration</p>
<p>T<span class="Sub">max</span>=time to reach C<span class="Sub">max</span></p>
<p>AUC (0-24)=area under the serum concentration-time curve from 0 h up to 24 h after daily multiple administration</p>
<p>t<span class="Sub">1/2</span>=half-life</p>
<p>N/A=Not available</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a18005c7-8999-491c-b9ae-4cddc207fadd"></a><a name="section-11.3.2"></a><p></p>
<h3>Effect of Food</h3>
<p class="First">The effect of food on the absorption and bioavailability of DRSP and E2 have not been investigated following the administration of Angeliq. However, clinical studies with different formulations containing DRSP or E2 have shown that the bioavailability of both drugs is not affected by concomitant food intake. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_49795c34-0c44-4c11-89c7-19a0e2533f1d"></a><a name="section-11.3.3"></a><p></p>
<h3>Distribution </h3>
<p class="First">The mean volume of distribution of DRSP is 4.2 L/kg. DRSP does not bind to SHBG or CBG but binds about 97% to other serum proteins. The distribution of exogenous estrogens is similar to that of endogenous estrogens. Estrogens are widely distributed in the body and are generally found in higher concentrations in the sex hormone target organs. Estradiol circulates in the blood bound to SHBG (37%) and to albumin (61%), while only approximately 1%<span class="Bold">–</span>2% is unbound. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6e4d2d1f-90ba-4d66-9b14-be039e4a7588"></a><a name="section-11.3.4"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Mean clearance of DRSP is 1.2 mL/min/kg. DRSP is extensively metabolized after oral administration. The two main metabolites of DRSP found in human plasma were identified to be the acid form of DRSP generated by opening of the lactone ring and the 4,5-dihydrodrospirenone-3-sulfate, formed by reduction and subsequent sulfation. These metabolites were shown not to be pharmacologically active. DRSP is also subject to oxidative metabolism catalyzed  by CYP3A4. </p>
<p>Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. </p>
<p>Excretion</p>
<p>DRSP serum concentrations are characterized by a terminal elimination half<span class="Bold">-</span>life of approximately 36<span class="Bold">–</span>42 hours. Excretion of DRSP was nearly complete after 10 days and amounts excreted were slightly higher in feces compared to urine. DRSP was extensively metabolized and only trace amounts of unchanged DRSP were excreted in urine and feces. At least 20 different metabolites were observed in urine and feces. About 38% to 47% of the metabolites in urine were glucuronide and sulfate conjugates. In feces, about 17% to 20% of the metabolites were excreted as glucuronides and sulfates. Estradiol, estrone, and estriol are excreted in the urine along with glucuronide and sulfate conjugates. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_789fc1e4-c2d6-4c0e-8133-7e79bac87c63"></a><a name="section-11.3.5"></a><p></p>
<h3>Use in Specific Populations </h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f993f60-b380-42de-9898-f670827d0c30"></a><a name="section-11.3.5.1"></a><p></p>
<h4><span class="Bold">Geriatric</span></h4>
<p class="First">No pharmacokinetic studies were conducted for Angeliq in the geriatric population. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f2f0f36-46f2-4be8-be5f-514157e542ae"></a><a name="section-11.3.5.2"></a><p></p>
<h4><span class="Bold">Pediatric</span></h4>
<p class="First">No pharmacokinetic studies were conducted for Angeliq in a pediatric population. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c3fdbff8-97b2-4874-9304-fe1d8f25f72f"></a><a name="section-11.3.5.3"></a><p></p>
<h4><span class="Bold">Gender</span></h4>
<p class="First">Angeliq is indicated for use in women only. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1dd3e53b-c735-404a-a3e9-5d0e61b5b88a"></a><a name="section-11.3.5.4"></a><p></p>
<h4><span class="Bold">Race</span></h4>
<p class="First">No studies were done to determine the effect of race on the pharmacokinetics of Angeliq. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e7ed1a32-07c9-48ae-831c-3d86faaf3cb6"></a><a name="section-11.3.5.5"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></h4>
<p class="First">Angeliq is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see Contraindications (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>) and Warnings and Precautions (<a href="#i4i_section_id_ac3343a4-0573-49b0-af06-e2b47e51979d">5.10</a>)].</span> The mean exposure to DRSP in women with moderate liver impairment is approximately three times the exposure in women with normal liver function. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_243081de-66bb-4335-a6f2-6ae2a5fd9a48"></a><a name="section-11.3.5.6"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></h4>
<p class="First">Angeliq is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Contraindications (<a href="#i4i_contraindications_id_eb2a0f74-0084-4eba-8e6b-3f77dba46084">4</a>) and Warnings and Precautions (<a href="#i4i_section_id_fe0b63b1-0fe6-451a-a56d-4e4782659505">5.2</a>)].</span></p>
<p>The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of DRSP (3 mg daily for 14 days) and the effects of DRSP on serum potassium concentrations were investigated in female subjects (n=28, age 30-65 years) with creatinine clearance (CLcr) ≥ 80 mL/min (11 patients), and CLcr of 50-79 mL/min (10 patients) and CLcr of 30-49 mL/min (7 patients). All subjects were on a low potassium diet. During the study 7 subjects continued the use of potassium-sparing drugs for the treatment of the underlying illness. On the 14th day (steady-state) of DRSP treatment, the serum DRSP concentrations were on average 37% higher in the group with CLcr of 30-49 mL/min compared to those in the group with normal renal function (CLcr ≥ 80 mL/min). Serum DRSP concentrations in the group with CLcr of 50-79 mL/min were comparable to those in the group with CLcr ≥ 80 mL/min. DRSP treatment was well tolerated by all groups. DRSP treatment did not show any clinically significant effect on serum potassium concentration. Although <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> was not observed in the study, in 5 of the 7 subjects who continued use of potassium sparing drugs during the study, individual mean serum potassium concentrations increased by up to 0.33 mEq/L. Therefore, potential exists for <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> to occur in subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> whose serum potassium is in the upper reference range, and who are concomitantly using potassium sparing drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b910ad8d-825a-41e8-b2c7-3c221adaab7a"></a><a name="section-11.3.6"></a><p></p>
<h3>Drug Interactions</h3>
<p class="First">No formal drug interaction studies have been conducted for Angeliq.</p>
<p><span class="Bold">Effects of Drospirenone on Other Drugs</span>: Metabolism of DRSP and potential effects of DRSP on hepatic CYP enzymes have been investigated in <span class="Italics">in vitro</span> and<span class="Italics"> in vivo</span> studies. In<span class="Italics"> in vitro </span>studies, DRSP did not affect turnover of model substrates of CYP1A2 and CYP2D6, but had an inhibitory influence on the turnover of model substrates of CYP1A1, CYP2C9, CYP2C19 and CYP3A4 with CYP2C19 being the most sensitive enzyme. </p>
<p>The potential effect of DRSP on CYP2C19 activity was investigated in a clinical pharmacokinetic study using omeprazole as a marker substrate. In the study with 24 postmenopausal women [including 12 women with homozygous (wild type) CYP2C19 genotype and 12 women with heterozygous CYP2C19 genotype] the daily oral administration of 3 mg DRSP for 14 days did not affect the systemic clearance of the CYP2C19 substrate omeprazole (40 mg) and the CYP2C19 product 5-hydroxy-omeprazole. Furthermore, no significant effect of DRSP on the systemic clearance of the CYP3A4 product omeprazole sulfone was found. These results demonstrated that DRSP did not inhibit CYP2C19 and CYP3A4 <span class="Italics">in vivo</span>. </p>
<p>Two further clinical drug-drug interaction studies using simvastatin and midazolam as marker substrates for CYP3A4 were each performed in 24 healthy, postmenopausal women. The results of these studies demonstrated that pharmacokinetics of the CYP3A4 substrates were not influenced by steady-state DRSP concentrations achieved after administration of 3 mg DRSP/day.</p>
<p>Based on the available results of <span class="Italics">in vivo</span> and <span class="Italics">in vitro</span> studies, it can be concluded that, at clinical dose concentration, DRSP is unlikely to inhibit significantly CYP enzymes.</p>
<p>There is a potential for an increase in serum potassium in women taking drospirenone with other drugs that may affect electrolytes, such as ACE inhibitors, angiotensin receptor blockers, or NSAIDs. </p>
<p>Electrolytes were studied in 230 postmenopausal women with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and/or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus requiring an ACE inhibitor or angiotensin receptor blocker. Of these, 26 patients had a creatinine clearance &gt;50 mL/min to &lt;80 mL/min. Patients were given 1 mg E2 and 3 mg DRSP (n=112) or placebo (n=118) over 28 days. Non-diabetic patients also received ibuprofen 1200 mg/day for 5 days during the study. There was a single case of serum potassium &gt;6 mEq/L and a single case of serum sodium &lt;130 mEq/L on treatment, both occurring following five days of ibuprofen therapy in two women taking E2/DRSP. Serum potassium concentrations ≥5.5 mEq/L were observed in 8 (7.3%) E2/DRSP-treated subjects (3 diabetic and 5 non-diabetic) and in 3 (2.6%) placebo-treated subjects (2 diabetic and 1 non-diabetic). After 28 days of exposure, the mean change from baseline in serum potassium was 0.11 mEq/L for the E2/DRSP group and 0.08 mEq/L for the placebo group. None of the subjects with serum potassium concentrations ≥5.5 mEq/L had cardiovascular adverse events. </p>
<p>A drug-drug interaction study of DRSP 3 mg/E2 1 mg versus placebo was performed in 24 mildly hypertensive postmenopausal women taking enalapril maleate 10 mg twice daily. Potassium concentrations were obtained every other day for a total of 2 weeks in all subjects. Mean serum potassium concentrations in the DRSP/E2 treatment group relative to baseline were 0.22 mEq/L higher than those in the placebo group. Serum potassium concentrations also were measured at multiple timepoints over 24 hours at baseline and on Day 14. On Day 14, the ratios for serum potassium C<span class="Sub">max</span> and AUC in the DRSP/E2 group to those in the placebo group were 0.955 (90% CI: 0.914, 0.999) and 1.01 (90% CI: 0.944, 1.08), respectively. No patient in either treatment group developed <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium concentrations &gt;5.5 mEq/L). </p>
<p>Of note, occasional or chronic use of NSAID medication was not restricted in any of the Angeliq clinical trials.</p>
<p><span class="Bold">Effects of Other Drugs on Estrogens and Progestins</span>:<span class="Italics"> In vitro and in vivo</span> studies have shown that estrogens and progestins are metabolized partially by CYP3A4. Therefore, inducers or inhibitors of CYP3A4 may affect estrogen and progestin drug metabolism <span class="Italics">[see Drug Interactions (7.1)].</span><span class="Bold"> </span>In a clinical drug-drug interaction study conducted in 18 premenopausal women, once daily co-administration of DRSP 3 mg/E2 1.5 mg combination tablets with strong CYP3A4 inhibitor, ketoconazole 200 mg twice daily for 10 days resulted in a 2.30-fold (90% CI: 2.08-2.54) increase of the AUC (0-24) and a 1.66-fold (90% CI: 1.50-1.84) increase of C<span class="Sub">max</span> for DRSP. The E2 exposure [that is, AUC (0-24) and C<span class="Sub">max</span>] was unaffected by ketoconazole, although the AUC(0-24) and C<span class="Sub">max</span> for E1 increased 1.39-fold (90% CI: 1.27-1.52) and 1.32-fold (90% CI: 1.23-1.42), respectively.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_e3d2bdee-2f4b-4d97-81db-646eddbfaf26"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_4847f353-2a66-4614-a23c-d4c5703f728b"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 24-month oral carcinogenicity study in mice dosed with 10 mg/kg/day DRSP alone or 1+0.01, 3+0.03 and 10+0.1 mg/kg/day of DRSP and ethinyl estradiol, 0.24 to 10.3 times the exposure (AUC of drospirenone) of women taking a 1 mg dose, there was an increase in carcinomas of the Harderian gland in the group that received the high dose of drospirenone alone. In a similar study in rats given 10 mg/kg/day drospirenone alone or 0.3+0.003, 3+0.03 and 10+0.1 mg/kg/day drospirenone and ethinyl estradiol, 2.3 to 51.2 times the exposure of women taking a 1 mg dose, there was an increased incidence of benign and total (benign and malignant) adrenal gland <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in the group receiving the high dose of drospirenone. Drospirenone was not mutagenic in a number of<span class="Italics"> in vitro </span>(Ames, Chinese Hamster Lung gene mutation and chromosomal damage in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>) and<span class="Italics"> in vivo</span> (mouse micronucleus) genotoxicity tests. Drospirenone increased unscheduled DNA synthesis in rat hepatocytes and formed adducts with rodent liver DNA but not with human liver DNA. </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_4b7dca17-6cda-4c8f-a774-cc557a93862b"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ce05056b-d455-4caa-b9f6-0ab196149ec8"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Effects on Vasomotor Symptoms </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2b9ff6c9-e935-4f0c-aa6a-41502ab17831"></a><a name="section-13.1.1"></a><p></p>
<h3>Angeliq 0.25 mg DRSP/0.5 mg E2</h3>
<p class="First">The efficacy of Angeliq 0.25 mg DRSP/0.5 mg E2 for reducing the frequency and severity of moderate to severe vasomotor symptoms was evaluated in a randomized, double-blind, placebo-controlled trial. A total of 735 postmenopausal women ≥ 40 years of age with a minimum of 7 to 8 moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> daily or 50 to 60 moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> weekly were randomized to one of the two doses of Angeliq, including DRSP 0.25 mg/0.5 mg E2, estrogen monotherapy, or placebo. The median age of study subjects was 53 years and 68% were Caucasian. Efficacy for vasomotor symptoms was assessed during the 12 weeks of treatment. Compared to placebo, subjects receiving Angeliq 0.25 mg DRSP/0.5 mg E2 achieved statistically significant reduction in the frequency and severity of moderate to severe vasomotor symptoms at Week 4 and at Week 12. The mean difference in daily reduction of frequency of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> between Angeliq 0.25 mg DRSP/0.5 mg E2 and placebo were approximately -2 episodes at Week 4 and -3 episodes at Week 12. Table 4 shows the mean number of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span> in the Angeliq 0.25 mg DRSP/0.5 mg E2 and placebo groups and the treatment difference between Angeliq 0.25 mg DRSP/0.5 mg E2 and placebo treatment at Week 4 and at Week 12.</p>
<a name="_Refid_511c6274-593d-46ba-8228-1aa0dd1fd"></a><table width="100%">
<caption><span>Table 4: Summary Tabulation Of The Number Of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flushes</span> Per Day - Mean Values And Comparisons Between the Active Treatment Group and the Placebo Group, Last Observation Carried Forward</span></caption>
<col width="34%">
<col width="13%">
<col width="16%">
<col width="23%">
<col width="15%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Mean change from baseline, difference from placebo, 95% confidence interval, and p-value based on an ANCOVA model with treatment and pooled center as factors and baseline measurement as covariate</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Treatment</p></td>
<td class="Botrule Rrule Toprule" colspan="4" valign="top"><p class="First">No. of <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot Flushes</span>/Day</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Time Period<br>(week) </p></td>
<td class="Botrule Rrule" valign="top"><p class="First">Baseline<br>Mean</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">Mean Change from Baseline<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Rrule" valign="top"><p class="First">Difference from Placebo (95% CI)</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">p-Values<br>vs. Placebo* </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">DRSP/E2 (0.25 mg/0.5 mg) [n=175]</p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"><p class="First"> </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Week 4</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">10.68</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">-5.46</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">-2.02  (-2.89, -1.16)</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">&lt;0.0001</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Week 12</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">10.68</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">-7.71</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">-3.17  (-3.97, -2.37)</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">&lt;0.0001</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Placebo [n=176]</p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> </p></td>
<td class="Botrule Rrule" valign="top"><p class="First"> </p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Week 4</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">10.53</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">-3.44</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">-</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"> Week 12</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">10.53</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">-4.54</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">-</p></td>
<td class="Botrule Rrule" valign="top"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="5" valign="top"></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0839fb97-d1ad-4da1-936b-5a346cf73f46"></a><a name="section-13.1.2"></a><p></p>
<h3>Angeliq 0.5 mg DRSP/1 mg E2</h3>
<p class="First">Support for treatment of vasomotor symptoms and vaginal and vulvar <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> was shown through bioequivalence of the E2 component of the Angeliq combination product with a currently marketed 1 mg E2 product. The multiple-dose bioequivalence study evaluated the bioequivalence of E2 from a tablet containing DRSP (2 mg) and E2 (1 mg) relative to E2 1 mg tablet. Angeliq 0.5 mg DRSP/1 mg E2 tablets met the criteria for bioequivalence to the E2 1 mg comparator. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a1d15cbf-dfd2-4cc0-a7cb-408e0f4a3a1f"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Effects on Endometrium</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_27330a14-72ba-4c0c-a9a2-bc746cab1198"></a><a name="section-13.2.1"></a><p></p>
<h3>Angeliq 0.25 mg DRSP/0.5 mg E2</h3>
<p class="First">In a one year clinical trial, 661 postmenopausal subjects were treated with Angeliq 0.25 mg DRSP/0.5 mg E2 (N=489) or a comparator drug (N=172). Endometrial biopsies were performed on 407 (83.2%) subjects in the Angeliq group during the treatment period. No <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasias</span> occurred during or after one year of treatment. See Table 5.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3a562cd1-c239-45b1-b0fb-8429c3e8c3b2"></a><a name="section-13.2.2"></a><p></p>
<h3>Angeliq 0.5 mg DRSP/1 mg E2</h3>
<p class="First">In a one year clinical trial of 1,142 postmenopausal subjects treated with 1 mg E2 alone or 1 mg E2 + 0.5, 1, 2, or 3 mg DRSP, endometrial biopsies were performed on 966 (84.6%) subjects during the treatment period. Eight subjects in the E2 monotherapy group developed <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> (4 simple <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> with no cytological atypia, 3 complex <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> with no cytological atypia, and 1 complex <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> with cytological atypia), and one subject in the 1 mg E2+2 mg DRSP group developed simple <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> with no cytological atypia. Table 5 shows that there were no diagnoses of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">endometrial hyperplasia</span> in the Angeliq group. </p>
<a name="_Refid_708c19ef-27eb-46d2-868a-2e9421b1a"></a><table width="100%">
<caption><span>Table 5: Incidence of <span class="product-label-link" type="condition" conceptid="200775" conceptname="Endometrial hyperplasia">Endometrial Hyperplasia</span> after up to 12 Months of Treatment </span></caption>
<col width="27%">
<col width="23%">
<col width="24%">
<col width="27%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Includes evaluable and unevaluable endometrial biopsy results</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">E2 1 mg</span></p></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">Angeliq 0.25 mg DRSP/</span><br><span class="Bold">0.5 mg E2</span></p></td>
<td class="Toprule" align="center" valign="top"><p class="First"><span class="Bold">Angeliq 0.5 mg DRSP/</span><br><span class="Bold">1 mg E2</span></p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">Total No. Subjects Treated</span></p></td>
<td align="center" valign="top"><p class="First">226</p></td>
<td align="center" valign="top"><p class="First">489</p></td>
<td align="center" valign="top"><p class="First">227</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Bold">Total No. of </span><br><span class="Bold">On-Treatment Biopsies</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></p></td>
<td align="center" valign="top"><p class="First">197 (87.2%)</p></td>
<td align="center" valign="top"><p class="First">407 (83.2%)</p></td>
<td align="center" valign="top"><p class="First">191 (84.1%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">Hyperplasia</span></span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">8 (4%)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">0 (0%)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">0 (0%)</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3b5a0721-d0bb-4835-aedf-02815a375bfa"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Effects on <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">Uterine Bleeding</span> or Spotting </h2>
<p class="First">Angeliq 0.5 mg DRSP/1 mg E2 and Angeliq 0.25 mg DRSP /0.5 mg E2 were evaluated in separate one-year clinical trials investigating the endometrial safety in postmenopausal women with an intact uterus.</p>
<p>Over 12 months in the double-blind trials, the proportions of women with any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting decreased over time. At one year, approximately 22% of women treated with Angeliq 0.5 mg/E2 1.0 mg and 15% of women treated with Angeliq 0.25 mg/E2 0.5 mg had any <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span> or spotting. See Figure 2.</p>
<div class="Figure">
<a name="id1931"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=761834c2-6b61-4583-84c2-f1ca4a97c4f2&amp;name=image-03.jpg"><p class="MultiMediaCaption">Figure 2: Proportion of Subjects with any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>/Spotting by Month of Angeliq Use</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fc35850c-b450-4195-8cea-40967a7e25cf"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Women's Health Initiative Studies</h2>
<p class="First">The WHI enrolled approximately 27,000 predominantly healthy postmenopausal women in two substudies to assess the risks and benefits of daily oral CE (0.625 mg)-alone or in combination with MPA (2.5 mg) compared to placebo in the prevention of certain chronic diseases. The primary endpoint was the incidence of CHD defined as nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>], with invasive breast cancer as the primary adverse outcome. A "global index" included the earliest occurrence of CHD, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, PE, endometrial cancer (only in the CE plus MPA substudy), colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other cause. These substudies did not evaluate the effects of CE plus MPA or CE-alone on <span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">menopausal symptoms</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9deb316b-4d14-40ce-946b-ec36fc1623d7"></a><a name="section-13.4.1"></a><p></p>
<h3>WHI Estrogen plus Progestin Substudy </h3>
<p class="First">The WHI estrogen plus progestin substudy was stopped early. According to the predefined stopping rule, after an average follow-up of 5.6 years of treatment, the increased risk of breast cancer and cardiovascular events exceeded the specified benefits included in the "global index." The absolute excess risk of events included in the “global index? was 19 per 10,000 women-years.</p>
<p>For those outcomes included in the WHI “global index? that reached statistical significance after 5.6 years of follow-up, the absolute excess risks per 10,000 women-years in the group treated with CE plus MPA were 7 more CHD events, 8 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, 10 more PEs, and 8 more invasive breast cancers, while the absolute risk reductions per 10,000 women-years were 6 fewer colorectal cancers and 5 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>.</p>
<p>Results of the CE plus MPA substudy, which included 16,608 women (average 63 years of age, range 50 to 79; 83.9 percent White, 6.8 percent Black, 5.4 percent Hispanic, 3.9 percent Other) are presented in Table 6. These results reflect centrally adjudicated data after an average follow-up of 5.6 years.</p>
<p> </p>
<a name="_Refid_4494b53d-9f72-44c5-859e-8ab98c264"></a><table width="100%">
<caption><span>Table 6: Relative and Absolute Risk Seen in the Estrogen Plus Progestin Substudy of WHI at an Average of 5.6 Years<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a><a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a></span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Results are based on centrally adjudicated data.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">§</a></dt>
<dd>Not included in "global index.?</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">¶</a></dt>
<dd>Includes metastatic and non-metastatic breast cancer, with the exception of <span class="Italics">in situ</span> breast cancer.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">#</a></dt>
<dd>All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">Þ</a></dt>
<dd>A subset of the events was combined in a "global index", defined as the earliest occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"><p class="First">Event</p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First">Relative Risk<br>CE/MPA vs. Placebo<br>(95% nCI<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a>)<br></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">CE/MPA<br> n=8,506 <br></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">Placebo<br> n=8,102 <br></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">Absolute Risk per 10,000 Women-Years</p></td></tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First">CHD events</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.23 (0.99–1.53)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">41</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">34</p></td>
</tr>
<tr>
<td class="Lrule Rrule" valign="top"><p class="First"><span class="Italics">Non-fatal MI</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Italics">1.28 (1.02–1.632)</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Italics">31</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Italics">25</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Italics">  CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Italics">1.10 (0.70–1.75)</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Italics">8</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Italics">8</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.31 (1.03–1.68)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">33</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">Ischemic stroke</span></span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.44 (1.09-1.90)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">26</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">18</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.95 (1.43-2.67)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">26</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2.13 (1.45–3.11)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">18</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Invasive breast cancer<a name="footnote-reference-10" href="#footnote-10" class="Sup">¶</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.24 (1.01-1.54)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">41</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">33</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Colorectal cancer</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.61 (0.42–0.87)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Endometrial cancer<a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.81 (0.48–1.36)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Cervical cancer<a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.44 (0.47-4.42)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span><a href="#footnote-8" class="Sup">‡</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.67 (0.47–0.96)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral fractures</span><a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.65 (0.46–0.92)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">17</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.71 (0.59-0.85)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">44</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">62</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-9" class="Sup">§</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.76 (0.69-0.83)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">152</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">199</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Overall Mortality<a name="footnote-reference-11" href="#footnote-11" class="Sup">#</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.00 (0.83-1.19)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">52</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">52</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Global Index<a name="footnote-reference-12" href="#footnote-12" class="Sup">Þ</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.13 (1.02-1.25)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">184</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">165</p></td>
</tr>
</tbody>
</table>
<p>Timing of the initiation of estrogen therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen plus progestin substudy stratified by age showed in women 50-59 years of age, a non-significant trend toward reduced risk for overall mortality <span class="Italics">[HR 0.69 (95 percent CT 0.44-1.07)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7b103365-182e-45cb-9932-41205cae331c"></a><a name="section-13.4.2"></a><p></p>
<h3>WHI Estrogen-Alone Substudy</h3>
<p class="First">The WHI estrogen-alone substudy was stopped early because an increased risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed, and it was deemed that no further information would be obtained regarding the risks and benefits of estrogen alone in predetermined primary endpoints. </p>
<p>Results of the estrogen-alone substudy, which included 10,739 women (average age of 63 years, range 50 to 79; 75.3 percent White, 15.1 percent Black, 6.1 percent Hispanic, 3.6 percent Other), after an average follow-up of 7.1 years are presented in Table 7.</p>
<a name="_Refid_4e663493-a8cb-462b-b1ae-be4844c50"></a><table width="100%">
<caption><span>Table 7. Relative and Absolute Risk Seen in the Estrogen-Alone Substudy of WHI<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a></span></caption>
<col width="33%">
<col width="25%">
<col width="21%">
<col width="21%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>Adapted from numerous WHI publications. WHI publications can be viewed at www.nhlbi.nih.gov/whi.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">†</a></dt>
<dd>Nominal confidence intervals unadjusted for multiple looks and multiple comparisons.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">‡</a></dt>
<dd>Results are based on centrally adjudicated data for an average follow-up of 7.1 years.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">§</a></dt>
<dd>Not included in “global index.?</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">¶</a></dt>
<dd>Results are based on an average follow-up of 6.8 years.</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">#</a></dt>
<dd>All <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, except from breast or colorectal cancer, definite or probable CHD, PE or cerebrovascular disease.</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">Þ</a></dt>
<dd>A subset of the events was combined in a "global index," defined as the earliest occurrence of CHD events, invasive breast cancer, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, colorectal cancer, <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fracture</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to other causes.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First">Event</p></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2" valign="top"><p class="First">Relative Risk<br>CE vs. Placebo<br><br>(95% nCI<a name="footnote-reference-14" href="#footnote-14" class="Sup">†</a>)</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">CE<br>n=5,310</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">Placebo<br>n=5,429</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">Absolute Risk per 10,000 Women-Years</p></td></tr>
<tr>
<td class="Lrule" valign="top"><p class="First">CHD events<a name="footnote-reference-15" href="#footnote-15" class="Sup">‡</a></p></td>
<td align="center" valign="top"><p class="First">0.95 (0.78–1.16)</p></td>
<td align="center" valign="top"><p class="First">54</p></td>
<td class="Rrule" align="center" valign="top"><p class="First">57</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First"><span class="Italics">Non-fatal MI</span><a href="#footnote-15" class="Sup">‡</a></p></td>
<td align="center" valign="top"><p class="First"><span class="Italics">0.91 (0.73–1.14)</span></p></td>
<td align="center" valign="top"><p class="First"><span class="Italics">40</span></p></td>
<td class="Rrule" align="center" valign="top"><p class="First"><span class="Italics">43</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Italics">CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></span><a href="#footnote-15" class="Sup">‡</a></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"><span class="Italics">1.01 (0.71–1.43)</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First"><span class="Italics">16</span></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First"><span class="Italics">16</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">All <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span><a href="#footnote-15" class="Sup">‡</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.33 (1.05–1.68)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">45</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">33</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Italics">Ischemic</span><a href="#footnote-15" class="Sup">‡</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.55 (1.19-2.01)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">38</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">25</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep vein thrombosis</span><a href="#footnote-15" class="Sup">‡</a><a name="footnote-reference-16" href="#footnote-16" class="Sup">§</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.47 (1.06-2.06)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">23</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">15</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span><a href="#footnote-15" class="Sup">‡</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.37 (0.90–2.07)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">10</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Invasive breast cancer<a href="#footnote-15" class="Sup">‡</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.80 (0.62-1.04)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">28</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">34</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Colorectal cancer<a href="#footnote-15" class="Sup">‡</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.08 (0.75–1.55)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">16</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">Hip fracture</span><a href="#footnote-15" class="Sup">‡</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.65 (0.45–0.94)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">19</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Vertebral fractures <a href="#footnote-15" class="Sup">‡</a><a href="#footnote-16" class="Sup">§</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.64 (0.44–0.93)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">18</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Lower arm/wrist <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-15" class="Sup">‡</a><a href="#footnote-16" class="Sup">§</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.58 (0.47-0.72)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">35</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">59</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Total <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span><a href="#footnote-15" class="Sup">‡</a><a href="#footnote-16" class="Sup">§</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">0.71 (0.64–0.8)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">144</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">197</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to other causes<a name="footnote-reference-17" href="#footnote-17" class="Sup">¶</a><a name="footnote-reference-18" href="#footnote-18" class="Sup">#</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.08 (0.88-1.32)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">53</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">50</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Overall Mortality<a href="#footnote-15" class="Sup">‡</a><a href="#footnote-16" class="Sup">§</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.04 (0.88-1.22)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">79</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">75</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Global Index<a name="footnote-reference-19" href="#footnote-19" class="Sup">Þ</a></p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">1.02 (0.92-1.13)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">206</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">201</p></td>
</tr>
</tbody>
</table>
<p>For those outcomes included in the WHI "global index" that reached statistical significance, the absolute excess risk per 10,000 women-years in the group treated with CE-alone was 12 more <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while the absolute risk reduction per 10,000 women-years was 7 fewer <span class="product-label-link" type="condition" conceptid="4138412" conceptname="Fracture of proximal end of femur">hip fractures</span>.<span class="Sup">9</span> The absolute excess risk of events included in the "global index" was a non-significant 5 events per 10,000 women-years. There was no difference between the groups in terms of all-cause mortality.</p>
<p>No overall difference for primary CHD events (nonfatal MI, silent MI and CHD <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) and invasive breast cancer incidence in women receiving CE-alone compared with placebo was reported in final centrally adjudicated results from the estrogen-alone substudy, after an average follow-up of 7.1 years.</p>
<p>Centrally adjudicated results for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> events from the estrogen-alone substudy, after an average follow-up of 7.1 years, reported no significant difference in distribution of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> subtype or severity, including fatal <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, in women receiving CE-alone compared to placebo. Estrogen-alone increased the risk for <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic stroke</span>, and this excess risk was present in all subgroups of women examined.<span class="Sup">10</span></p>
<p>Timing of the initiation of estrogen therapy relative to the start of <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may affect the overall risk benefit profile. The WHI estrogen-alone substudy stratified by age showed in women 50 to 59 years of age, a non-significant trend toward reduced risk for CHD <span class="Italics">[HR 0.63 (95 percent CI 0.36-1.09)]</span> and overall mortality <span class="Italics">[HR 0.71 (95 percent CT 0.46-1.11)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_10f61d52-7c42-4600-abb0-9537178bee54"></a><a name="section-13.5"></a><p></p>
<h2>14.5 Women's Health Initiative Memory Study </h2>
<p class="First">The WHIMS estrogen plus progestin ancillary study of WHI enrolled 4,532 predominantly healthy postmenopausal women 65 years of age and older (47 percent were 65 to 69 years of age, 35 percent were 70 to 74 years of age, and 18 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) plus MPA (2.5 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to placebo.</p>
<p>After an average follow-up of 4 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA versus placebo was 2.05 (95 percent CI 1.21-3.48). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE plus MPA was 45 versus 22 cases per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included Alzheimer’s disease (AD, <span class="product-label-link" type="condition" conceptid="379778" conceptname="Multi-infarct dementia">vascular dementia</span> (VaD) and mixed type (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the treatment group and the placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (5.4), and Use in Specific Populations (8.5)]</span>. </p>
<p>The WHIMS estrogen-alone ancillary study of WHI enrolled 2,947 predominantly healthy hysterectomized postmenopausal women 65 to 79 years of age and older (45 percent were age 65 to 69 years of age, 36 percent were 70 to 74 years of age, and 19 percent were 75 years of age and older) to evaluate the effects of daily CE (0.625 mg) on the incidence of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (primary outcome) compared to placebo. </p>
<p>After an average follow-up of 5.2 years, the relative risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 1.49 (95 percent CI, 0.83 - 2.66). The absolute risk of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years. Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> as defined in this study included AD, VaD, and mixed type (having features of both AD and VaD). The most common classification of probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> in the treatment group and placebo group was AD. Since the ancillary study was conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>) and Use in Specific Populations (<a href="#i4i_geriatric_use_id_953cda66-db43-4afe-998c-fc07588263ab">8.5</a>)]</span>.</p>
<p>When data from the two populations were pooled as planned in the WHIMS protocol, the reported overall RR for probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> was 1.76 (95 percent CI 1.19-2.60). Differences between groups became apparent in the first year of treatment. It is unknown whether these findings apply to younger postmenopausal women <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_ac0eef72-a398-4789-9b42-314911e2bbd9">5.4</a>) and Use in Specific Populations (<a href="#i4i_geriatric_use_id_953cda66-db43-4afe-998c-fc07588263ab">8.5</a>)]</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_ec09643b-4537-4cae-bf50-a46acefb2784"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Rossouw JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">Menopause</span>. <span class="Italics">JAMA</span>. 2007;297:1465-1477. </dd>
<dt>2.</dt>
<dd>Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. <span class="Italics">Arch Int Med</span>. 2006;166:357-365. </dd>
<dt>3.</dt>
<dd>Cushman M, et al. Estrogen Plus Progestin and Risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span>. <span class="Italics">JAMA</span>. 2004;292:1573-1580</dd>
<dt>4.</dt>
<dd>Curb JD, et al. <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">Venous Thrombosis</span> and Conjugated Equine Estrogen in Women Without a Uterus. <span class="Italics">Arch Int Med</span>. 2006;166:772-780. </dd>
<dt>5.</dt>
<dd>Chlebowski RT, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women. <span class="Italics">JAMA</span>. 2003;289:3234-3253. </dd>
<dt>6.</dt>
<dd>Stefanick ML, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. <span class="Italics">JAMA</span>. 2006;295:1647-1657. </dd>
<dt>7.</dt>
<dd>Anderson GL, et al. Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures. <span class="Italics">JAMA</span>. 2003;290:1739-1748. </dd>
<dt>8.</dt>
<dd>Shumaker SA, et al. Conjugated Equine Estrogens and Incidence of Probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> and Mild <span class="product-label-link" type="condition" conceptid="443432" conceptname="Impaired cognition">Cognitive Impairment</span> in Postmenopausal Women. <span class="Italics">JAMA</span>. 2004;291:2947-2958. </dd>
<dt>9.</dt>
<dd>Jackson RD, et al. Effects of Conjugated Equine Estrogen on Risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> and BMD in Postmenopausal Women With Hysterectomy: Results From the Women's Health Initiative Randomized Trial. <span class="Italics">J Bone Miner Res</span>. 2006;21:817-828. </dd>
<dt>10.</dt>
<dd>Hendrix SL, et al. Effects of Conjugated Equine Estrogen on <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in the Women's Health Initiative. <span class="Italics">Circulation</span>. 2006;113:2425-2434. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_45615001-fd4a-427f-af59-4057ac19c053"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ba47fc6-81b0-4372-abcc-840254dd43f7"></a><a name="section-15.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Angeliq is supplied in packages of three blisterpacks: </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b7ff8db3-b2b0-480f-ab45-5266552c8176"></a><a name="section-15.1.1"></a><p></p>
<h3>Angeliq 0.25 mg DRSP/0.5 mg E2 </h3>
<p class="First">Angeliq 0.25 mg DRSP/0.5 mg E2 tablets are available as round, biconvex yellow film-coated tablets embossed with "EL" inside a hexagon. </p>
<p>3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> of 28 tablets NDC 50419-482-03</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_03957855-3c18-4f7f-847e-196c2002205d"></a><a name="section-15.1.2"></a><p></p>
<h3>Angeliq 0.5 mg DRSP/1 mg E2</h3>
<p class="First">Angeliq 0.5 mg DRSP/1 mg E2 tablets are available as round, biconvex pink film-coated tablets embossed with "CK" inside a hexagon. </p>
<p>3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> of 28 tablets NDC 50419-483-03 </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1cd6e2f7-e2bd-44fc-a60d-461a5f9cc85f"></a><a name="section-15.2"></a><p></p>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store at 25° C (77° F); excursions permitted to 15–30° C (59–86° F) [see USP Controlled Room Temperature]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_c1ba75c1-fb43-4ef4-a29b-74ebd8848f20"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See “FDA-Approved Patient Labeling (Patient Information).? </p>
<p><span class="Bold">Abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></span></p>
<p>Inform postmenopausal women of the importance of reporting abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to their healthcare provider as soon as possible <span class="Italics">[see Warning and Precautions (5.3)].</span></p>
<p><span class="Bold">Possible Serious Adverse Reactions with Estrogen Plus Progestin Therapy</span></p>
<p>Inform postmenopausal women of possible serious adverse reactions of estrogen plus progestin therapy including <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span>, malignant neoplasms, and probable <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> <span class="Italics">[see Warning and Precautions (5.1, 5.3, 5.4)].</span></p>
<p><span class="Bold">Possible Less Serious but Common Adverse Reactions with Estrogen Plus Progestin Therapy</span></p>
<p>Inform postmenopausal women of possible less serious but common adverse reactions of estrogen plus progestin therapy such as <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> <span class="Italics">[see Adverse Reactions (6)].</span></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_20fe2dba-27d7-42dc-83bd-44a748a6826a"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">FDA-Approved Patient Labeling<br>PATIENT INFORMATION</span></p>
<p><span class="Bold">Angeliq<span class="Sup">®</span> (an"ju–le–k') </span><br><span class="Bold">(drospirenone and estradiol)</span></p>
<p><span class="Bold">Tablets</span></p>
<p>Read this Patient Information before you start taking Angeliq and each time you refill your Angeliq prescription. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p>
<div class="Warning">
<a name="id_c686f17b-a85a-4273-8af0-998270ee4d9a"></a><a name="section-17.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">What is the most important information I should know about Angeliq (combination of estrogen and progestin hormones)?</span></p>
<dl>
<dt>•</dt>
<dd>Do not use estrogens with progestins to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span> (declines of brain function)</dd>
<dt>•</dt>
<dd>Using estrogens with progestins may increase your chances of getting <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, breast cancer, or blood clots </dd>
<dt>•</dt>
<dd>Using estrogens with progestins may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women 65 years of age or older</dd>
<dt>•</dt>
<dd>Do not use estrogen-alone to prevent heart disease, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span></dd>
<dt>•</dt>
<dd>Using estrogen-alone may increase your chance of getting cancer of the uterus (womb)</dd>
<dt>•</dt>
<dd>Using estrogen-alone may increase your chances of getting <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> or blood clots</dd>
<dt>•</dt>
<dd>Using estrogen-alone may increase your chance of getting <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, based on a study of women 65 years of age or older</dd>
<dt>•</dt>
<dd>You and your healthcare provider should talk regularly about whether you still need treatment with Angeliq</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="id_bf42179f-b9dd-494b-b5da-560b5d981ef9"></a><a name="section-17.1"></a><p></p>
<p class="First"> </p>
<p><span class="Bold">What is Angeliq?</span></p>
<p>Angeliq is a medicine that contains 2 kinds of hormones, estrogen and progestin. </p>
<dl>
<dt>•</dt>
<dd>Angeliq 0.25 mg drospirenone (DRSP)/0.5 mg estradiol (E2) and Angeliq 0.5 mg DRSP/1 mg E2 are both used after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> to reduce moderate to severe <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>.</dd>
<dt>•</dt>
<dd>Estrogens are hormones made by a woman's ovaries. The ovaries normally stop making estrogens when a woman is between 45 to 55 years old. This drop in body estrogen levels causes the "change of life" or <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> (the end of monthly menstrual periods). Sometimes, both ovaries are removed during an operation before natural <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> takes place. The sudden drop in estrogen levels causes "<span class="product-label-link" type="condition" conceptid="440155" conceptname="Postartificial menopausal syndrome">surgical menopause</span>."</dd>
<dt>•</dt>
<dd>When the estrogen levels begin dropping, some women develop very uncomfortable symptoms, such as feelings of warmth in the face, neck, and chest, or sudden strong feelings of heat and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> ("<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>" or "<span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flushes</span>"). In some women, the symptoms are mild, and they will not need estrogens. In other women, symptoms can be more severe. You and your healthcare provider should talk regularly about whether you still need treatment with Angeliq.</dd>
<dt>•</dt>
<dd>Angeliq 0.5 mg drospirenone (DRSP)/1 mg estradiol (E2) is used after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> to treat moderate to severe dryness, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and burning in or around the vagina. You and your healthcare provider should talk regularly about whether you still need treatment with Angeliq to control these problems. If you use Angeliq only to treat dryness, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and burning in and around your vagina, talk with your healthcare provider about whether a topical vaginal product would be better for you.</dd>
</dl>
<p><span class="Bold">Who should not take Angeliq? </span></p>
<p>Do not start taking Angeliq if you:</p>
<dl>
<dt>•</dt>
<dd>have had your uterus removed (hysterectomy). </dd>
<dt>•</dt>
<dd>Angeliq contains a progestin to decrease the chances of getting cancer of the uterus. If you do not have a uterus, you do not need a progestin and you should not use Angeliq.</dd>
<dt>•</dt>
<dd>have unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span> after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span> may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> to find out the cause.</dd>
<dt>•</dt>
<dd>currently have or have had certain cancers. Estrogens may increase the chances of getting certain types of cancers, including cancer of the breast or uterus. If you have or had cancer, talk with your healthcare provider about whether you should take Angeliq.</dd>
<dt>•</dt>
<dd>had a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> in the past year.</dd>
<dt>•</dt>
<dd>currently have or have had blood clots.</dd>
<dt>•</dt>
<dd>have kidney disease, liver disease, or disease of your adrenal glands. Angeliq contains drospirenone which may increase the potassium level in your blood. Liver, kidney, or adrenal gland disease may also increase the potassium level in your blood.</dd>
<dt>•</dt>
<dd>have been diagnosed with a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder.</dd>
<dt>•</dt>
<dd>are allergic to Angeliq or any of its ingredients. See the end of this leaflet for a list of ingredients in Angeliq.</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant.</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking Angeliq? </span></p>
<p>Before you take Angeliq, tell your healthcare provider if you:</p>
<dl>
<dt>•</dt>
<dd>have or have had problems with your adrenal glands. </dd>
<dt>•</dt>
<dd>have high levels of fat in your blood (triglycerides)</dd>
<dt>•</dt>
<dd>have any other medical conditions. Your healthcare provider may need to check you more carefully if you have certain conditions, such as: <dl>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (<span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>)</dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>)</dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span></dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span></dd>
<dt>∘</dt>
<dd>lupus</dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (high blood pressure)</dd>
<dt>∘</dt>
<dd>problems with your heart, liver, thyroid or kidneys</dd>
<dt>∘</dt>
<dd>benign breast disease</dd>
<dt>∘</dt>
<dd>have high calcium in your blood</dd>
<dt>∘</dt>
<dd>have high potassium levels in your blood</dd>
<dt>∘</dt>
<dd>have low sodium levels in your blood</dd>
</dl>
</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. Angeliq is not for pregnant women. If you think you may be pregnant, you should have a pregnancy test and know the results before you start taking Angeliq.</dd>
<dt>•</dt>
<dd>are breastfeeding or planning to breastfeed. You should not breastfeed while taking Angeliq. The hormone in Angeliq can decrease the amount of breast milk you make. Also, the hormone in Angeliq can pass into your milk. Talk to your healthcare provider about the best way to feed your baby if you take Angeliq.</dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and nonprescription medicines, vitamins, and herbal supplements. Some medicines may affect how Angeliq works. Some other medicines and food products may increase or decrease the concentrations of the hormones in Angeliq in the blood. Angeliq may also affect how your other medicines work. Angeliq may increase the potassium level in your blood and some medicines may also increase potassium level.  In some situations, your healthcare provider may recommend testing your blood for potassium level.</p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">If you are going to have surgery or will be on bed rest.</span> Your healthcare provider will let you know if you need to stop taking Angeliq.</p>
<p><span class="Bold">How should I take Angeliq?</span></p>
<dl>
<dt>•</dt>
<dd>Take one Angeliq tablet at the same time each day.</dd>
<dt>•</dt>
<dd>Take Angeliq tablets whole. Do not break, crush, dissolve, or chew Angeliq tablets before swallowing. If you cannot swallow Angeliq tablets whole, tell your healthcare provider. You may need a different medicine.</dd>
<dt>•</dt>
<dd>If you miss a dose of Angeliq, take it as soon as possible.</dd>
<dt>•</dt>
<dd>If more than 24 hours have passed since you missed a dose of Angeliq, you should not take the missed dose. </dd>
<dt>•</dt>
<dd>Estrogens should be used at the lowest dose possible for your treatment only as long as needed. You and your healthcare provider should talk regularly (for example, every 3 to 6 months) about whether you still need treatment with Angeliq. </dd>
</dl>
<p><span class="Bold">What are the possible side effects of Angeliq?</span></p>
<p><span class="Bold">Angeliq may cause serious side effects. </span></p>
<p><span class="Bold">Serious but less common side effects include:</span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attack</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> </dd>
<dt>•</dt>
<dd>Blood clots </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> </dd>
<dt>•</dt>
<dd>Breast cancer </dd>
<dt>•</dt>
<dd>Cancer of the lining of the uterus (womb) </dd>
<dt>•</dt>
<dd>Cancer of the ovary </dd>
<dt>•</dt>
<dd>High blood pressure </dd>
<dt>•</dt>
<dd>High blood sugar</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></dd>
<dt>•</dt>
<dd>Liver problems</dd>
<dt>•</dt>
<dd>Enlargement of benign tumors of the uterus (“fibroids?)</dd>
</dl>
<p><span class="Bold">Call your healthcare provider right away if you have any of the following warning signs or any other unusual symptoms that concern you: </span></p>
<dl>
<dt>•</dt>
<dd>New <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> </dd>
<dt>•</dt>
<dd>Changes in vision or speech </dd>
<dt>•</dt>
<dd>Sudden new severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> </dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span> in your chest or legs with or without <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> </dd>
</dl>
<p><span class="Bold">Less serious, but common side effects include:</span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span></dd>
<dt>•</dt>
<dd>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting </dd>
<dt>•</dt>
<dd>Stomach or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></dd>
<dt>•</dt>
<dd>Vaginal <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">yeast infection</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid Retention</span></dd>
<dt>•</dt>
<dd>Moodiness</dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of Angeliq. For more information, ask your healthcare provider or pharmacist about side effects.</p>
<p>You may report side effects to Bayer HealthCare Pharmaceuticals at 1-888-842-2937 or to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">How should I store Angeliq? </span></p>
<p>Store Angeliq at room temperature between 59˚F to 86˚F (15˚C to 30˚C).</p>
<p><span class="Bold">Keep Angeliq and all medicines out of the reach of children. </span></p>
<p><span class="Bold">What can I do to lower my chances of a serious side effect with Angeliq?</span></p>
<dl>
<dt>•</dt>
<dd>Talk with your healthcare provider regularly about whether you should continue taking Angeliq. </dd>
<dt>•</dt>
<dd>See your healthcare provider right away if you get <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> while taking Angeliq. </dd>
<dt>•</dt>
<dd>Have a pelvic exam, breast exam and mammogram (breast X-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or an abnormal mammogram, you may need to have breast exams more often. </dd>
<dt>•</dt>
<dd>If you have high blood pressure, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (fat in the blood), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances for getting heart disease. </dd>
</dl>
<p><span class="Bold">General information about the safe and effective use of Angeliq.</span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take Angeliq for conditions for which it was not prescribed. Do not give Angeliq to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about Angeliq. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about Angeliq that is written for health professionals. </p>
<p>For more information, go to www.angeliq-us.com by or calling our toll free number (1-888-842-2937).</p>
<p><span class="Bold">What are the ingredients in Angeliq?</span></p>
<p>Active ingredients: drospirenone (a progestin) and estradiol. </p>
<p>Inactive ingredients 0.5 mg DRSP/1 mg E2 tablets: lactose monohydrate NF, corn starch NF, pregelatinized starch NF, povidone 25000 USP, magnesium stearate NF, hydroxylpropylmethyl cellulose USP, macrogol 6000 NF, talc USP, titanium dioxide USP, and ferric oxide pigment NF. </p>
<p>Inactive ingredients in 0.25 mg DRSP/0.5 mg E2 tablets: lactose monohydrate NF, corn starch NF, pregelatinized starch NF, povidone 25000 USP, magnesium stearate NF, hydroxylpropylmethyl cellulose USP, macrogol 6000 NF, talc USP, titanium dioxide USP, and yellow ferric oxide pigment NF.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured for:</p>
<p>Bayer HealthCare Pharmaceuticals Inc.<br>Whippany, NJ 07981</p>
<p>©2015 Bayer HealthCare Pharmaceuticals Inc.<br>All rights reserved.</p>
<p>June 2015</p>
<p>Bayer HealthCare Pharmaceuticals Inc.</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_cb91eb8a-2fda-4f3b-bad2-062fbe48bb58"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">Angeliq 1's Trade Carton</span></p>
<p>NDC 50419-483-01</p>
<p>1 Unit</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Angeliq<span class="Sup">®</span> Tablets</span></p>
<p><span class="Bold">(Drospirenone and Estradiol)</span></p>
<p><span class="Bold">0.5 mg/1 mg</span></p>
<p>— 0.5 mg/1 mg</p>
<p>— 28 tablets</p>
<p>— oral</p>
<div class="Figure">
<a name="id2592"></a><img alt="Angeliq 1's trade" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=761834c2-6b61-4583-84c2-f1ca4a97c4f2&amp;name=image-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_de4b6bfa-9532-428e-9431-2f3b2290f831"></a><a name="section-19"></a><p></p>
<h1>n</h1>
<p class="First"><span class="Bold">Angeliq 1's Trade Carton</span></p>
<p>NDC 50419-482-01</p>
<p>1 Unit</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Angeliq<span class="Sup">®</span> Tablets</span></p>
<p><span class="Bold">(Drospirenone and Estradiol)</span></p>
<p><span class="Bold">0.25 mg/0.5 mg</span></p>
<p>— 0.25 mg/0.5 mg</p>
<p>— 28 tablets</p>
<p>— oral</p>
<div class="Figure">
<a name="id2623"></a><img alt="Angeliq 0.25/0.5 mg carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=761834c2-6b61-4583-84c2-f1ca4a97c4f2&amp;name=image-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ANGELIQ 		
					</strong><br><span class="contentTableReg">drospirenone and estradiol tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50419-483</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL</td>
<td class="formItem">1 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>DROSPIRENONE</strong> (DROSPIRENONE) </td>
<td class="formItem">DROSPIRENONE</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K25</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">CK</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50419-483-03</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50419-483-01</td>
<td class="formItem">28  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50419-483-72</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50419-483-71</td>
<td class="formItem">14  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021355</td>
<td class="formItem">11/28/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ANGELIQ 		
					</strong><br><span class="contentTableReg">drospirenone and estradiol tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50419-482</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ESTRADIOL</strong> (ESTRADIOL) </td>
<td class="formItem">ESTRADIOL</td>
<td class="formItem">0.5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>DROSPIRENONE</strong> (DROSPIRENONE) </td>
<td class="formItem">DROSPIRENONE</td>
<td class="formItem">0.25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K25</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 6000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">EL</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50419-482-03</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50419-482-01</td>
<td class="formItem">28  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50419-482-72</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50419-482-71</td>
<td class="formItem">14  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021355</td>
<td class="formItem">02/29/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bayer HealthCare Pharmaceuticals Inc.
							(005436809)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bayer Weimar GmbH und Co. KG</td>
<td class="formItem"></td>
<td class="formItem">331485631</td>
<td class="formItem">MANUFACTURE(50419-483, 50419-482)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6d15eb36-1591-4da2-9055-e2518eff570d</div>
<div>Set id: 761834c2-6b61-4583-84c2-f1ca4a97c4f2</div>
<div>Version: 7</div>
<div>Effective Time: 20150702</div>
</div>
</div> <div class="DistributorName">Bayer HealthCare Pharmaceuticals Inc.</div></p>
</body></html>
